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1 Introduction 
1.1 GTP-binding proteins (GNBPs) 
Guanine nucleotide binding proteins are involved in a wide range of intracellular processes 
including signal transduction1, vesicular transport2, cell growth and differentiation3, receptor 
mediated endocytosis4, protein synthesis5 and protein targeting6. Over 200 different small 
GTP-binding proteins, or small GTPases, have been indentified in eukaryotic cells7. Most of 
these proteins cycle between a GDP-bound ‘OFF’ state and a GTP-bound ‘ON’ state by using 
a conserved switch mechanism (Figure 1.1)8. Only the GTP-bound form can interact with 
downstream effector molecules and carry out signal transduction. 
 
Figure 1.1: Schematic representation of the GTPase cycle. Cycling of switch GTPases occurs between an 
‘Off’ state and an ‘On’ state. Intrinsic slow activation by GDP dissociation is accelerated by guanine 
nucleotide exchange factors (GEFs) and slow intrinsic GTP hydrolysis is accelerated by GTPase activating 
proteins (GAPs). GDP dissociation is inhibited by guanine nucleotide dissociation inhibitors (GDIs) in 
some cases. 
The GTPases are activated by the exchange of GDP for GTP, in which an intrinsically slow 
nucleotide exchange process is accelerated by guanine nucleotide exchange factors (GEFs). 
The GTPases are deactived by the hydrolysis of GTP to GDP, in which an intrinsically slow 
hydrolysis of GTP to GDP is accelerated by GTPase activating proteins (GAPs). GAP 
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catalysed rates of hydrolysis of up to 100,000-fold over the intrinsic rate have been observed9. 
In some cases (members of the Rho and Rab families), another set of regulators, guanine 
nucleotide dissociation inhibitors (GDIs) are involved in the cycle. These molecules stably 
bind to GTPases preventing GDP dissociation and mask the attached isoprenyl group, thereby 
increasing the solubility of GNBPs (see 1.2)10;11. 
The members of the Ras superfamily are central regulators of diverse important cellular 
processes. Over 170 small GTP-binding proteins have been identified in mammalian cells and 
subclassified on the basis of sequence into the Ras, Rho12;13, Rab14;15, Arf16;17, and Ran 
families18-20. Comparative analysis of primary sequences within the superfamily reveals a 
conserved primary structure with 30-55% sequence identity. Within the Ras family, each 
protein shares high sequence similarity with 50-55% amino acid identity, whereas the Rho 
and Rab family members share ~30% amino acid identity with the Ras family members21. 
Similar to the other GTPases the members of the Ras superfamily have consensus amino acid 
sequences responsible for specific interaction with GDP and GTP and for GTP cleavage8;21. In 
addition, the members of the Ras, Rho and Rab subfamily undergo post-translational lipid 
modifications such as farnesylation, geranylgeranylation or palmitoylation at their C-
termini22;23, whereas Arf proteins undergo myristoylation at the N-terminal glycine residue24. 
1.2 Rab proteins 
Rab proteins form the largest family of monomeric small GTPases in the Ras superfamily. 
Eleven Rab (Yptp/Sec4p) proteins have been identified in the yeast Saccharomyces cerevisiae 
and at least 60 in humans25. Following protein synthesis and lipid modification Rab proteins 
are localized to distinct intracellular compartments and regulate intracellular vesicular 
transport between organelles26 (Figure 1.2). 
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Figure 1.2: Intracellular localization of Rab proteins in mammalian cells adopted from25. Some Rabs are 
cell specific (Rab3a in neurons), tissue specific (Rab17 in epithelia) or cell-type-specific localization 
(Rab13 in tight junctions). 
Newly synthesized GDP-bound Rab proteins bind to Rab Escort Protein REP, which mediates 
their post-translational lipid modification and membrane association. One or two C-terminal 
cysteine residues of all Rab proteins are prenylated using GGPP as a lipid donor (see 1.6.2). 
The geranylgeranylated Rab proteins are escorted to be localized to specific intracellular 
membranes by REP, which sequesters the insoluble geranylgeranyl moiety to a hydrophobic 
tunnel and helps to stabilize Rab proteins in a soluble form. Once the geranylgeranylated Rab 
protein is presented to the specified target membrane, REP dissociates from Rab and recycles 
to the cytosol for additional rounds of Rab escorting (Figure 1.3, steps 1–4). REP proteins 
share sequence homology with another type of Rab regulatory protein, Rab GDP dissociation 
inhibitor (RabGDI). Similar to REP, RabGDI binds GDP-bound Rab proteins, solubilising the 
hydrophobic geranylgeranyl groups and producing soluble RabGDI:Rab:GDP complexes in 
the cytosol. However, in contrast to REP, the main function of GDI is extraction of Rab:GDP 
from intracellular membranes and its re-delivery to donor membranes (Figure 1.3, steps 11–
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14). Major conformational changes in RabGDI are thought to occur upon binding to 
membrane associated Rab:GDP, resulting in the dissociation of the RabGDI:Rab:GDP 
complex from acceptor membranes27. Recycling of Rab:GDP proteins to specific target 
membrane compartments is a process which is not yet understood in detail. Factors which are 
thought to play a role are RabGDI displacement factor (GDF), which may serve as 
RabGDI:Rab:GDP receptors28;29 and specific exchange factors30 localized on individual 
membranes. Upon binding to donor membrane receptors, RabGDI dissociates from Rab:GDP 
and becomes available for additional rounds Rab:GDP extraction and transport. 
In addition to cycling between distinct intracellular compartments, all Rab proteins also cycle 
between the inactive GDP-bound and the active GTP-bound state in a similar manner to other 
GTPases (Figure 1.3, steps 5–10). The rate of nucleotide exchange from GDP to GTP is 
greatly accelerated by specific guanine nucleotide exchange factors (GEFs). The GTP-bound 
Rab proteins interact with their specific effector molecules facilitating transport, tethering, 
and fusion of vesicles at their appropritate destination31-33 (see below). GTP hydrolysis results 
in the return of Rab proteins to the inactive GDP-bound state. The intrinsic rate of GTP 
hydrolysis is greatly accelerated by GTPase activating proteins (GAPs). 
Introduction
 
 
 
5
 
Figure 1.3: Rab prenylation, membrane localization and nucleotide cycling. First, REP recognizes newly 
synthesized GDP-bound Rab proteins (1) and presents them to RabGGTase (2). Following their 
geranylgeranylation, Rab proteins are escorted by REP and localized to their specific donor membrane by 
inserting of lipid residues (3). REP dissociates from Rab and is available for additional rounds of Rab 
escort (4). Subsequently, Rab proteins undergo nucleotide exchange from GDP to GTP mediated by GEFs 
(5–7). GTP-bound Rab proteins interact with effector molecules facilitating transport, tethering, and 
fusion of vesicles at their appropritate destination (8-9). The slow intrinsic GTP hydrolysis is accelerated 
by GAPs, resulting in dissociation of effector molecules from Rab proteins (10). The extraction of GDP-
bound Rab proteins from acceptor membranes is mediated by GDI, which solubilizes Rabs and delivers 
them back to the donor membrane (11). GDF mediates the dissociation of GDI from Rab proteins and the 
reinserting of Rab proteins into the donor membrane (12), and GDI is available for additional rounds of 
Rab extraction (13,14). 
Vesicular transport can be divided into four essential steps, consisting of vesicle budding, 
transport, tethering and fusion (Figure 1.4)34;35. RabGTPases have been shown to be involved 
in the regulation of each of these steps36. 
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During vesicle budding several Rabs are involved in vesicle formation37-40. Rab4 and its 
interactor rabaptin-5/rabex-5 complex regulate the receptor recycling from endosomes back to 
the plasma membrane, which is mediated by adaptor protein (AP)-1/clathrin-coated vesicles. 
Rab4 is required for the generation of the endosome-derived vesicles40. Several studies 
suggest that Rabs also play a role in cargo selection. The affinity between a cargo selection 
protein TIP47 (tail-interacting protein of 47 kDa) and its cargo mannose 6-phosphate 
receptors (MPRs) is enhanced by the binding of TIP47 to a GTP-bound Rab937;41. This 
indicates that Rab9 stimulates cargo capture by the enhancement of the affinity of TIP47 for 
its cargo. 
Following budding the vesicles are transported to their target membranes along the 
cytoskeleton (Figure 1.4), i.e. either along microtubules or actin42;43. Molecular motors, 
including kinesin, dynein and myosin, and several RabGTPases have been implicated in this 
process. Both isoforms of Rab6, Rab6a and Rab6a’, can stimulate microtubule-dependent 
Golgi-to-ER transport. These two isoforms of Rab6 regulate the association of their effector 
proteins (BicD) to the motor complex dynein-dynactin44. A recent study revealed that two 
Rabs (Rab7 and Rab27a) regulate the transport of melanosome by controlling two different 
motor proteins45. Rab7 recruits the motor complex dynein-dynactin through its effector Rab7-
interacting lysosomal protein (RILP)46 and regulates the microtubule-mediated transport of 
early melanosomes. Rab27a then regulates the subsequent actin-dependent transport of 
mature melanosomes by controlling myosin Va motor protein mediated by Rab27a effectors 
(melanophilin/Slac2-a)47-49. In addition, it is also proposed that Rab7 is involved in late 
endocytic transport through the binding of its effector RILP to the motor complex dynein-
dynactin50. 
The next step, tethering, is a process that brings a carrier vesicle and its specific target 
membrane into close proximity. Several Rab proteins play a critical role in the initial 
recognition between a vesicle and its target membrane by the interaction of GTP-bound Rab 
on the vesicle with a tethering factor (also called tether) on the target membrane. Tethering 
factors are divided into two categories: large multisubunit complexes and long coiled-coil 
proteins34;36;51. Seven of eight identified tethering factors of large multisubunit complexes 
serve as Rab effectors, including the Exocyst, COG, GARP/VFT, HOPS, CORVET, TRAPPI, 
and TRAPPII. One example of a Rab effector of the long coiled-coil protein class is the 
tethering factor p115. GTP-bound Rab1 binds to p115 to recruit p115 into carrier vesicles52. 
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Following tethering the carrier vesicle undergoes membrane fusion with the target organelle 
mediated by soluble N-ethylmaleimide-sensitive factor attachment protein receptors 
(SNAREs)53. The crystal structure of SNAREs reveal that it is folded into a four-helical 
coiled-coil bundle54;55. The interaction network formed by one arginine (R) and three 
glutamines (Q) from the four helices plays a central role for association of the helices to a 
bundle. Based on the presence of the arginine and glutamine the four helices fall into two 
groups: R- and Q-SNAREs56. Before formation of trans-SNARE complexes (the helices of 
the bundle located on different membrane) by vesicular v-SNAREs and target t-SNAREs, the 
cis-SNARE complexes (the helices of the bundle located on same membrane) are 
disassembled mediated by the ATPase NSF (N-ethylmaleimide sensitive fusion protein) and 
its cochaperone α-SNAP (soluble NSF-attachment protein)57. This process is called initial 
priming (Figure 1.4)57. Subsequently, the disassembled cis-SNAREs complexes form the 
trans-SNAREs complexes. At last, a pore is formed by exerting of a mechanical force on the 
membranes through the tight association of trans-SNAREs complexes58 and the cargos are 
delivered to target organelle. Although several lines of evidence suggest that RabGTPases are 
involved in the membrane fusion process25;59-61, the exact functions of the RabGTPases at this 
point in the mechanism have not yet been determined. 
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Figure 1.4: RabGTPases in regulation of vesicular trafficking. The four steps of vesicle trafficking are 
consisted of vesicle budding, transport along the cytoskeleton, membrane tethering and fusion of the two 
membranes. 
1.3 Protein prenyltransferases 
Protein prenylation is a type of lipid modification involving covalent addition of either 
farnesyl (15-carbon) or geranylgeranyl (20-carbon) isoprenoids via a thioether linkage to 
cysteine residues at or near the C-terminus of intracellular proteins. Farnesyl and 
geranylgeranyl groups are polyisoprenes, unsaturated hydrocarbons with a repeating unit of 
five carbons; the chain is 15 carbons long in the farnesyl moiety and 20 carbons long in the 
geranylgeranyl moiety (see Table 1.1)62. The importance of prenylation is due to the 
involvement of prenylated proteins (such Ras, Rho and Rab) in critical cellular pathways and 
diseases63;64. Prenylation is necessary for the proper functions of prenylated protein. 
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Table 1.1: Comparison of the three protein prenyltransferases in mammalian cells. 
 Farnesyltransferase 
(FTase) 
Geranylgeranyltransferase I 
(GGTase-I) 
Geranylgeranyltransferase II 
(GGTase-II or RabGGTase) 
Subunit 
composition 
(mammalian) 
48 kDa (α) 
46 kDa (β) 
48 kDa (α) 
43 kDa (β) 
65 kDa (α) 
37 kDa (β) 
Protein 
substrate 
motif 
C-terminal 
–CA1 A2X box 
C-terminal 
–CA1 A2X box 
C-terminal such as –CC, -
CXC, -CCX, -CCXX, -
CCXXX, or –CXXX 
Examples of 
protein 
substrates 
Ras, nuclear lamins, 
Rhodopsin kinase, 
kinetochore proteins 
Rho, Rac, Rap, heterotrimeric G 
protein γ subunit 
Rab 
Lipid donor 
substrate 
Farnesyl diphosphate 
(FPP) 
O P O P O-
O
O-
O
O-  
Geranylgeranyl diphosphate 
(GGPP) 
O P O P O-
O
O-
O
O-  
Geranylgeranyl diphosphate 
(GGPP) 
O P O P O-
O
O-
O
O-  
Metal 
requirements 
Zn2+, Mg2+ Zn2+ Zn2+ 
Reaction 
OPOP-O
O
O-
O
O-
Protein substrate
SH
Protein substrate
S
+ OHPOP-O
O
O-
O
O-
+
 
Lipid anchors can mediate the subcellular localization of proteins. Other lipid modifications, 
such as myristoylation65;66 and palmitoylation67;68, are mainly important for association of the 
protein to membranes. However, it appears that the prenylation mediated by protein 
prenyltransferases has a more complex role69-71. On the one hand, the conjugated lipid 
residues (farnesyl or geranylgeranyl group) is required for membrane localization of the 
modified protein; on the other hand, the lipid group takes part in the specific protein-protein 
interactions based on either a direct interaction between lipid chains and proteins or 
conformational changes caused by prenylation72-76.  
The protein prenyltransferases in mammals are divided into three types. Protein 
farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase-I) both recognize a 
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‘CA1A2X’ motif on their protein substrates, and are thus called CAAX prenyltransferases77-79. 
Many members of the Ras superfamily of small GTPases are farnesylated by FTase, such as 
H-Ras, K-Ras, N-Ras, Ras2, Rap2, RhoB (which is also maybe geranylgeranylated), RhoE, 
Rheb, TC10, and TC21. Other typical protein substrates for farnesylation mediated by FTase 
include the nuclear lamina proteins lamin A and B, the kinetochore proteins CENP-E and 
CENP-F, fungal mating factors, cGMP phosphodiesterase, the α and γ subunit of trimeric G 
proteins, DnaJ heat-shock protein homologs, rhodopsin kinase and the peroxisomal membrane 
proteins Pex19 and PxF62. Small GTPases, such as Rac1, Rac2, RalA, Rap1A, Rap1B, RhoA, 
and RhoB, RhoC, Cdc42, are geranylgeranylated by GGTase-I. Some γ-subunit variants of 
trimeric G proteins, cGMP phosphodiesterase β and the plant calmodulin CaM53, are also 
protein substrates for GGTase-I. Rab8, Rab11 and Rab13 can be geranylgeranylated by both 
GGTase-I and RabGGTase62. 
Following prenylation mediated by CAAX protein prenyltransferases the prenylated proteins 
are delivered to their specific membrane, where the prenylated proteins usually undergo the 
cleavage of the C-terminal tripeptide (-A1A2X) catalysed by a prenyl-protein-specific 
protease. Subsequently, the C-terminal prenylcysteine is methylated under the catalyse of 
isoprenylcysteine carboxyl methyltransferase80-83. Palmitoylation is another lipid modification 
that is often combined with prenylation84. 
In the case of RabGGTase the recognition of the protein substrate is mediated by Rab escort 
protein (REP)85;86. There is no pronounced sequence conservation in the C-termini of Rab 
proteins. The C-terminus contains a prenylation motif often arranged as -CC, -CXC, -CCX, -
CCXX, -CCXXX or, in a few cases, with only a single cysteine as in -CXXX. Thus 
RabGGTase is sometimes referred to as a non-CAAX prenyltransferase22.  
All protein prenyltransferases are heterodimers formed by two subunits, α and β. The α 
subunit of FTase and GGTase-I is encoded by the same gene (see Table 1.1). Each 
prenyltransferase is a zinc-metal enzyme. Zinc ions are essential for the catalytic activity of 
all protein prenyltransferases (see 1.6). In addition, Mg2+ ion is required for optimal 
enzymatic activity of FTase87. 
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1.4 Structural features of protein prenyltransferases 
During the last decade, crystal structures of FTase and GGTase-I in complex with lipid 
substrates, protein substrates, and prenylated products have been determined at high 
resolution88;89. These structures help us to understand the prenylation process mediated by 
CAAX prenyltransferases. However, to date only the apo structure of RabGGTase and its 
structure as a complex with REP-1 are available due to technical difficulties associated with 
crystallisation of RabGGTase90. 
1.4.1 Overall structures of protein prenyltransferase  
The overall structures of FTase and GGTase-I are very similar and largely composed of α 
helices89;91. The structures of the α subunits in both enzymes are almost identical, with minor 
differences caused by the association with different β subunits. The α subunit consists of 14 α 
helices and is folded into seven successive pairs that form a series of righthanded antiparallel 
coiled coils. These coiled coils adopt a crescent-shaped superhelix and surround the β subunit 
(Figure 1.5). The α and β subunits associate through a large interface (burying >3,000 Å2 
surface area). 
The α subunit of RabGGTase (567 amino acids) is much larger than that of FTase and 
GGTase-I (377 amino adids). The structure of RabGGTase reveals that the α subunit of 
RabGGTase is folded into three domains: a helical domain, an immunoglobulin-like (IG) 
domain and a leucine-rich repeat (LRR) domain90. Despite the only 22% sequence identity 
between the α subunit of FTase and the respective helical domain in the α subunit of 
RabGGTase, they are structurally very similar. In comparison with FTase and GGTase-I, the 
most striking difference in RabGGTase is the presence of two additional domains of the α 
subunit: the IG domain and the LRR domain. These two domains are absent both in CAAX 
protein prenyltransferases and in lower eukaryote versions of RabGGTase. The functions of 
the additional domains in RabGGTase is unclear, however the structural studies reveal that 
they are not directly involved in the interaction with lipid donor, protein substrates or the Rab 
prenylation mediator REP90;92;93. The IG domain is composed of 115 amino acids (238α to 
352α) and LRR domain 126 (442α to 567α). Both domains are composed mainly of β sheets 
(Figure 1.5C). The IG domain is inserted into the helical domain and connects helices α11 and 
α12 by two loops, whereas the LRR domain is arranged at the C-terminus of the α subunit. 
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Figure 1.5: Overall structures of mammalian FTase (A), GGTase-I (B) and RabGGTase (C) and their zinc 
ion binding sites. Protein and zinc ion are shown as cartoons and as a magenta sphere, respectively. The 
zinc ion is coordinated by three conserved residues (insets): D297β, C299β, and H362β in FTase; D269β, 
C271β, and H321β in GGTase-I and D238β, C240β, and H290β in RabGGTase, which are shown as stick 
representation. The LRR and IG domains of RabGGTase are coloured in red and cyan, respectively. 
The β subunits of the three protein prenytransferases include the major parts of the protein 
substrate- and isoprenoid-binding pockets. Most of the residues responsible for substrate 
binding are in the β subunits89-91. Despite ca. 30% sequence identity among the β subunits of 
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the three protein prenyltransferases, they share similar overall structures. The structures of the 
β subunits consist of 14 α helices in FTase, 13 in GGTase-I and 12 in RabGGTase. These α 
helices are similarly folded into an α-α barrel containing a funnel-shaped, hydrophobic cavity 
lined by numerous conserved aromatic residues (Figure 1.5). 
1.4.2 Zinc binding site 
FTase, GGTase-I and RabGGTase are zinc metalloenzymes94;95. Crystal structures of these 
three enzymes reveal that one Zn2+ ion is localized near the α/β subunit interface and is 
coordinated by three strictly conserved residues: Asp297β, Cys299β, and His362β in FTase91; 
Asp269β, Cys271β, and His321β in GGTase-I89 and Asp238β, Cys240β, and His290β in 
RabGGTase90 (Figure 1.5). In the structures of the three enzymes a conserved hydrogen bond 
is formed between the zinc-coordinated histidine residue and an aspartic acid residue 
(Asp359β in FTase, Asp318β in GGTase-I; and Asp287β in RabGGTase). This coordination 
possibly has a stabilizing effect on zinc binding motif. 
1.5 Substrate specificity 
1.5.1 Isoprenoid diphosphate substrate specificity 
The structures of FTase and GGTase-I in complex with their respective isoprenoid substrate 
(FPP and GGPP) have been determined (PDB code: 1FT2 and 1N4P, respectively)89;96. Both 
structures show that the lipid chain of isoprenoid inserts into the central hydrophobic funnel 
of the α-α barrel of the β subunit, and the diphosphate group of the isoprenoid intreracts 
through hydrogen bonds with a positively charged cluster formed by two lysines and one 
arginine. The isoprene chain of FPP and GGPP interacts with a number of conserved aromatic 
residues in the funnel. In the case of FPP it adopts an extended conformation and in the case 
of GGPP a bent conformation with an angle of ca. 90° at the C15 of GGPP. 
Although both FPP and GGPP bind tightly to all prenyltranferases, the transfer efficiencies 
are very different23;94;97-100. FTase can only use FPP as a lipid donor for prenylation. In 
contrast, both GGTase-I and RabGGTase can prenylate their protein substrates using GGPP 
and FPP as lipid substrates, but with significant differences in efficiency. 
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1.5.2 Protein substrate specificity 
As mentioned above, the recognition of protein substrates by RabGGTase is indirect and 
mediated by Rab escort protein (REP)85;86, which occurs as two isoforms: REP-1 and REP-2. 
This is in harmony with the observation that RabGGTase has no pronounced sequence 
conservation in the C-termini of Rab proteins and RabGGTase displays no affinity for 
GTPases. 
Both FTase and GGTase-I recognize a CA1A2X motif in their protein substrate. Numerous 
structural studies on the binding of a series of CA1A2X peptides towards FTase and GGTase-I 
reveal the mechanism and rules of protein substrate selection by CAAX protein 
prenyltransferases. The selection rules have been applied in the identification of novel 
potential protein substrates for CAAX prenylatransferases within the human genome. The 
CA1A2X peptides in the structural studies are derived from the C-terminus of protein 
substrates for FTase or GGTase-I and have been cocrystallized with the enzymes in the 
presence of an unreactive isoprenoid analogue88;89;101-103. 
The ternary complexes show that all CA1A2X motifs bind to the active sites of FTase and 
GGTase-I in a similar mode. In all cases, the cysteine thiol is coordinated by the catalytic 
Zn2+ ion, activating the thiol group to form the thioether linkage (see 1.6). The C-terminus of 
CA1A2X motif inserts into the funnel. 
The residue A1 is solvent-exposed and this suggests that it can be any amino acid. This 
conclusion is consistent with biochemical studies89;97;101;102. The residue A2 binding sites in 
FTase and GGTase-I are similar in nature. Although the selection of A2 residues by both 
enzymes is restrained, this residue has very little effect on CAAX specificity. The residue A2 
for FTase and GGTase-I can be a variety of amino acids, such as valine, isoleucine, leucine, 
methionine, praline, phenylalanine, tyrosine and threonine, consistent with biochemical 
studies89;104. 
The X residue is inserted into the bottom of the hydrophobic funnel of the β subunit.The 
structures show that due to steric hinderance, the residue X binding site in both FTase and 
GGTase-I can not accommodate bulky amino acids, such as tyrosine, tryptophan, and 
arginine. The residue X binding site in FTase is more polar, in GGTase-I more hydrophobic. 
As a result, FTase and GGTase-I select CA1A2X motifs as their respective substrates primary 
through the recognition of the X residue by enzyme residues in the active site. This selection 
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is achieved by polar and hydrophobic interactions between the X residue and the enzyme side 
chains. For FTase, the residue X is usually methionine, serine or glutamine, in some case is 
also can be alanine, threonine, asparagine, histidine or cysteine. In contrast, for GGTase-I, the 
X position is usually leucine or phenylalanine (in a few case isoleucine or valine). 
1.6 Mechanism of the prenylation reaction 
1.6.1 Prenylation by CAAX-prenyltransferases 
Based on the biochemical results and the complex structures of both CAAX prenytransferases 
along the prenylation process, a reaction pathway was proposed for FTase and GGTase-
I88;89;98;99;105-108. The reaction pathway of FTase mediated protein prenylation obtained from 
the combination of structural data is schematically represented in Figure 1.688. 
 
Figure 1.6: Structures along the FTase mediated prenylation reaction adopted from Long et al. 88. In all 
complexes88;89;96;102 only the substrates and products are displayed in stick representation. In the apo 
enzyme structure (0) (PDB code 1FT1), the α subunit and the β subunit are shown in red and blue, 
respectively. Firstly, FPP associates to the active site (1) (PDB code 1FT2), followed by binding of the 
CAAX peptide (2) (PDB code 1D8D). The resulting farnesylated peptide remains bound in the 
hydrophobic cavity (3) (PDB code 1KZP). The binding of a new FPP displaces the attached lipid chain 
from the cavity (4) (PDB code 1KZO). ╪ represents a putative transition state between 2 and 3. The 
isoprenoid is shown in blue, the CAAX in yellow, and the catalytic zinc ion in magenta. Kinetic constants 
were taken from available biochemical data98;99;105;106;109;110. 
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Several biochemical studies reveal that the binding of substrates in CAAX prenyltransferases 
occurs in an ordered binding mechanism98;99;105-108, first isoprenoid substrate binds to the 
active site of enzyme, followed by the CAAX motif (Figure 1.6, complexes 1 and 2). The 
ordered binding mechanism is consistent with the structural analysis. In the structure of the 
enzyme in complex with a CAAX peptide and an unreactive isoprenoid analogue the 
isoprenoid makes extensive van der Waals contacts with the CAAX peptide. The cysteine 
thiol is coordinated by Zn+ ion and thus is activated. 
Following the binding of both isoprenoid substrate and CAAX peptide to the active site, a 
conformational change is required for the prenylation reaction. Comparison of the structure of 
CAAX prenyltransferase in complex with isoprenoid and CAAX peptide to the structure of 
the enzyme bound to the prenylated CAAX peptide reveals that the conformation and position 
of CAAX peptide backbone is almost identical before and after the prenylation reaction 
(Figure 1.7 A). Thus for the transition state it is hypothesized that the isoprenoid chain rotates 
at its third isoprene unit in the case of FTase or fourth in the case of GGTase-I and moves the 
C1 atom of isoprenoid closer to the activated thiolate of the CAAX peptide88;89. Subsequently, 
the prenylation reaction is carried out to form the prenylated product (Figure 1.6, complex 3). 
However, it is still unclear whether the reaction is through an electrophilic or a nucleophilic 
mechanism106;111;112. 
After cleavage of the bond between the C1 atom and the α-phosphate of isoprenoid the 
negative charges of the diphosphate group are stabilised by residues located at the active site 
of the enzymes, including a lysine (Lys164α in both FTase and GGTase-I) and a tyrosine 
(Tyr300β in FTase, Tyr272β in GGTase-I). Biochemical studies reveal that only FTase 
requires Mg2+ ion for its full catalytic activity78;94. This can be explained by stabilization of 
the developing negative charge of the diphosphate group of FPP. Structural analysis reveals 
that one Mg2+ ion interacts with the Asp352β of the FTase and the diphosphate group of 
FPP88. The corresponding position in GGTase-I is occupancied by the residue lysine 
(Lys311β), which stabilises the diphosphate group of GGPP. As a result, the catalytic activity 
of GGTase-I is Mg2+-independent. This conclusion is consistent with several mutagenesis 
studies, in which the enzyme activity of one mutant (FTaseK352β) is Mg2+-independent and the 
other mutant (GGTase-ID311β) becomes Mg2+-dependent113;114. 
Kinetic results indicate that product release is the rate-limiting step of the prenylation and 
occurs via the competitive binding of new substrate(s) to the active site, particularly 
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isoprenoid substrate98;107;108;110;115;116;116;117. Structural analysis of FTase and GGTase-I in 
complex with both isoprenoid substrate and prenylated product reveals that binding of a new 
isoprenoid substrate to the hydrophobic funnel shifts the attached lipid chain of the prenylated 
product to an ‘exit groove’ on the β subunit (Figure 1.6, complex 4, Figure 1.7 B))88;89. 
Finally, release of the prenylated product is facilitated by the competitive binding of a new 
CAAX peptide. 
Figure 1.7: Binding of substrates and products at active site of FTase. (A) In FTase, FPP (yellow) 
undergoes a conformational change and brings the C1 atom of FPP closer to the activated thiolate of the 
CAAX peptide (blue) (PDB code 1D8D) to form a prenylated product (orange and magenta) (PDB code 
1KZP). (B) Binding of a fresh FPP and translocated product in FTase (PDB code 1KZO). The active site 
of FTase is displayed in surface representation88. The attached lipid chain of the prenylated product is 
translocated to a conserved ‘exit groove’ by competitive binding of a new FPP molecule (yellow). 
1.6.2 Geranylgeranylation by RabGGTase 
The Rab prenylation mechanism is fundamentally different from that of the CAAX protein 
prenyltransferases. An additional protein factor, REP, is needed for Rab prenylation and 
usually Rab proteins undergo double geranylgeranylation118. A Rab protein, REP and 
RabGGTase associate as a ternary protein complex during Rab geranylgeranylaion. 
Numerous biochemical and structural studies were focused on the process of the formation of 
the ternary protein complex119. 
Based on available biochemical results two possible mechanisms were proposed for the 
formation of the ternary protein complex (Figure 1.8)120-126. In the ‘classical’ mechanism of 
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Rab prenylation, the unprenylated Rab interacts with REP first, followed by association of 
this complex with RabGGTase. The affinity of REP for RabGGTase is increased by the 
binding of either Rab or GGPP. This observation has led to proposition of an ‘alternative’ 
mechanism for the formation of the ternary protein complex123, that REP associates with 
RabGGTase bound to GGPP to form a binary protein complex followed by binding to Rab 
protein. However,the physiological significance of the presence of these two mechanism is 
still unclear92. 
 
Figure 1.8: Kinetic constants for RabGGTase catalysed Rab prenylation. Based on available biochemical 
data two possible mechanisms (‘classical’ and ‘alternative’mechanism) were proposed for the formation of 
the ternary protein complex between a Rab, REP and RabGGTase120-126. 
Several years ago the structure of REP-1 in complex with RabGGTase bound to a 
nonhydrolyzable isoprenoid analogue93 and the structures of REP-1 complexed with either 
un- or mono-prenylated Rab7127 gave insight into the RabGGTase catalysed Rab 
geranylgeranylation mechanism. The structural analysis reveals that the complex of Rab:REP 
is formed by the interactions between the Rab binding platform (RBP) of REP and the 
effector loops of Rab and between  the C-terminal binding region (CBR) of REP and the CBR 
interacting motif (CIM) of Rab, which is composed of two hydrophobic residues near the C-
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terminus of Rab proteins127;128. The association of RabGGTase with REP-1 is through the 
interaction of three helices of the RabGGTase α subunit and two helices of REP-1 domain 
II93. Remarkably, the surface area buried by the interface of the complex REP-1:RabGGTase 
is very small, around 680 Å2. 
The catalytic ternary complex between Rab, REP and RabGGTase can be modeled by 
superimposition of the Rab:REP and REP:RabGGTase complexes (Figure 1.9). In this model, 
the flexible C-terminus of Rab associates with the active site of RabGGTase during the 
geranylgeranylation reaction. The lipid binding site of REP-1 is located in domain II formed 
by five helices (D, E, F, G and H) (Figure 1.9). The distance between the REP-1 domain II 
and the active site of RabGGTase is around 30 Å, suggesting that after prenylation the 
translocation of the geranylgeranylated C-terminus of Rab proteins from the active site of 
RabGGTase to the domain II of REP-1 is a barrier. This is supported by biochemical studies, 
which show that product release by RabGGTase is very slow124;129. 
Analysis of the RabGGTase:REP-1 complex indicates that the interaction between two 
residues of REP-1 (Phe279 and Arg290), which are located on helices of domain II, and the α 
subunit of RabGGTase is critical for the association of REP-1 towards RabGGTase93;122. 
Following the geranylgeranylation reaction, the conjugated lipid chains are displaced from the 
hydrophobic funnel of the enzyme by competitive binding of a new isoprenoid substrate124, 
and are translocated to the lipid binding site of REP-1. The geranylgeranyl groups insert into 
the hydrophobic cavity of domain II (Figure 1.9), resulting in dilation of this cavity and in 
conformational changes of Phe279REP-1 and Arg290REP-1. This leads to a decrease in the 
affinity of RabGGTase towards the prenylated Rab:REP complex and facilitates product 
release by the enzyme. 
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Figure 1.9: Putative model of the ternary Rab7:REP-1:RabGGTase complex. All proteins are displayed in 
cartoon form. Domain I and domain II of REP-1 are coloured in green and cyan, respectively; the 
isoprenoid binding site of REP-1 is highlighted and the geranylgeranyl lipid (magenta) bound to the 
domain II is shown in stick representation. The α and β subunits of RabGGTase are coloured in dark blue 
and light blue, respectively; GGPP (magenta) in the putative site of RabGGTase is displayed in stick form 
and Zn2+ is shown as a magenta sphere. GDP (atomic colours) and the Mg2+ (light cyan) bound to Rab7 
(yellow) are shown in stick and sphere representation, respectively. The Rab7 C-terminus in the 
unprenylated complex (orange line) is expected to associate with the active site of RabGGTase. The 
putative position of the prenylated C terminus of Rab is shown as a red line. 
1.7 Protein prenyltransferases inhibitors 
Following the observation that farnesylation is required for the activity of oncogenic Ras 
proteins71;106;130;131, the development of FTase inhibitors became an active field of research. 
Recently GGTase-I has been also recognized as a promising anti-cancer target132.  
Several members of Ras subfamily are involved in human cancer, including K-Ras, N-Ras 
and H-Ras. Biochemical studies reveal that over 30 % of all human cancers are related to Ras 
mutational activation133. The GTP-bound active form of Ras proteins is stablized by the 
Introduction
 
 
 
21
mutations134. Constitutively activating mutations of Ras proteins have been identified in 
numerous human cancers including pancreatic cancer, non-small-cell lung cancer, colorectal 
cancer, melanoma, hepatocellular cancer, myelodysplastic syndrome and acute myelogenous 
leukaemia, follicular and undifferentiated papillary thyroid cancer, bladder cancer and renal 
cell cancer134-136. 
Human cancers are also related to the deregulation of Rho proteins, including breast cancer, 
colon cancer, lung cancer, bladder cancer, testicular germ cell cancer, melanoma cancer137-140. 
Unlike the Ras subfamily, so far, only one Rho subfamily member, RhoH, has been observed 
to be altered genetically in human cancer137;141;142. Usually the deregulation of Rho proteins is 
related to overexpression of Rho proteins and their regulators, or is related to mutations of 
their regulators. These regulators include GEFs143;144, GAPs145;146 and GDIs147;148. 
Recent studies demonstrates that the Rab proteins are also involved in human cancer136;149. 
One example is Rab25, which is overexpressed at the RNA level in human ovarian and breast 
cancer150. Overexpression of Rab25 induced an increase in cell proliferation and prevention of 
apoptosis. The other examples include the overexpression of Rab5a and Rab7 in thyroid 
adenomas151 and the upregulation of Rab1b, Rab4b, Rab10, Rab22a, Rab24 and Rab25 in 
hepatocellular carcinomas and cholangiohepatomas152. 
A number of FTase inhibitors and GGTase-I inhibitors have been developed over the past 
decade153-156. Based on their inhibitory mechanism these inhibitors can be divided into 
different classes. For example, some inhibitors inhibit prenytransferases by competitive 
binding with either isoprenoid substrate or CAAX peptides, in some cases with both 
substrates. One another class of inhibitors coordinates the catalytic zinc ion to inhibit the 
enzyme activity. Some of the identified FTase or GGTase-I inhibitors are being evaluated in 
clinical trials as anticancer157-161, antiparasitic162-164, antifungal165;166, and antiviral167;168 
therapeutic agents. Several FTase inhibitors displaying high inhibitory activity, such as 
R115777 (tipifarnib), SCH66336 (lonafarnib) and BMS214662 are currently as anticancer 
candidates in clinical phase II or III studies169. A few effective and specific inhibitors of 
GGTase-I have also been developed170. However, till now only one specific but weak 
phosphonocarboxylate inhibitor of RabGGTase, NE10790, has been identified171. 
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Figure 1.10: FTase or GGTase-I in complex with inhibitors currently evaluated in anticancer clinical 
trials. The α subunit (green) and β subunit (cyan) of FTase or GGTase-I are in cartoon representation, 
Zn2+ is shown as a magenta ball. Inhibitors and FPP are represented in atomic colours. The complex 
structures revealed a molecular basis for the inhibitory activities of the inhibitors. 
Introduction
 
 
 
23
The crystal structures of FTase or GGTase-I in complex with several inhibitors have been 
determined 154;155;172 (Figure 1.10). Analysis of these complexes reveals the inhibitory 
mechanism of the inhibitors. The availability of such structures should facilitate the 
development of more effective and selective inhibitors by structure-guided ligand design. 
Many developed inhibitors display dual specificity. For example, compound L-778,123 
inhibits both FTase and GGTase-I154. Remarkably, the crystal structures of FTase and 
GGTase-I in complex with this inhibitor indicate that it inhibits the enzymes through different 
mechanisms (Figure 1.10).In the case of FTase this inhibitor is competitive with the CAAX 
motif, whereas in the case of GGTase-I it is competitive with the isoprenoid substrate. The 
Bristol-Myers Squibb compounds, such as BMS1, BMS2, BMS3 and BMS4, are also 
inhibitors with dual-specificity and inhibit both FTase and RabGGTase131. 
During the development of BMS inhibitors, several compounds displayed proapoptotic 
activity in human cancer cells. However, the activity was not induced by inhibition of either 
FTase or GGTase-I173. Similar proapoptotic effects were observed by knockdown of 
RabGGTase gene and specific Rab protein genes131;174-176. Several biochemical and genetic 
studies indicate that the proapoptotic activity of the BMS compounds is related to their 
inhibition of RabGGTase131;176. These studies demonstrate that inhibition of RabGGTase can 
induce apoptosis in human cancer cells, and suggest that RabGGTase is a promising anti-
cancer target. 
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2 Aims of the project 
Despite significant progress, RabGGTase remains the least studied prenyltransferase and the 
exact mechanism of substrate selection and product release remains unclear. The lack of 
structural information is in part due to difficulties in obtaining high quality crystals of 
RabGGTase. 
This project firstly aims to address the mechanism of REP mediated Rab geranylgeranylation 
by determination of the structures of RabGGTase in the apo form and in complex with 
phosphoisoprenoids, including the native lipid donor GGPP, as well as FPP, GGMP and 
GGTP. Such structures would give mechanistic insights into lipid substrate specificity of 
RabGGTase, the mode of isoprenoid binding to RabGGTase, explain the large difference in 
affinity of the farnesyl and geranylgeranyl moieties and complete the pictures of 
substrate:enzyme complexes for the protein prenyltransferase family. 
Secondly, the structure of RabGGTase in complex with both the intermediate and the final 
product, namely mono- and di-prenylated peptides mimicing the mono- and di-prenylated 
Rab, should increase our understanding of the Rab prenylation reaction pathway. 
More recent studies validated RabGGTase enzyme as a promising target for anti-cancer 
therapy131. To study the role of RabGGTase in cancer, as well as the biological function of 
Rabs, potent and selective inhibitors of the enzyme with activity in cells would be invaluable. 
In addition, specific inhibitors of RabGGTase may have potential medical application. 
However, currently such compounds are not available131. Thus the third aim of this project is 
the structural determination of RabGGTase in complex with potential inhibitors. Such 
structures would reveal the molecular basis for the inhibition, potentially allowing 
development of more effective and selective inhibitors for RabGGTase by structure-guided 
ligand design. 
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3 Materials and methods 
3.1 Materials 
3.1.1 Bacterial strains 
E. coli Strain Genotype Company 
BL21 CodonPlus 
(DE3) RIL 
B F- ompT hsdS(rB- mB-) dcm+Tetr E. coli gal λ 
(DE3) endAHte [argU ileY leuWCamr] 
Stratagene 
XL1 Blue 
recA1, endA1, gyrA96, thi-1, hsdR17, supE44, 
relA1, lac [F´, proAB, lacIqZ∆M15, Tn10 (Tetr)] 
Stratagene 
3.1.2 Media and antibiotics 
LB (Luria-Bertani) medium 10 g/l tryptone 
10 g/l NaCl 
5 g/l yeast-extract 
LB Plattenagar 10 g/l tryptone 
10 g/l NaCl 
5 g/l extract 
20 g/l agar 
TB (terrific broth) medium 12 g/l tryptone 
24 g/l yeast-extract 
0.4% (v/v) glycerol 
2.31 g/l KH2PO4 
12.54 g/l K2HPO4 
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Antibiotics 
Ampicillin 125 mg/l medium 
Kanamycin 50 mg/l medium 
Chloramphenicol 35 mg/l medium 
3.1.3 Biochemicals and chemicals 
Unless otherwise noted all chemicals were purchased from Aldrich (Steinheim), Amersham-
Pharmacia (Freiburg), Boehringer Mannheim (Mannheim), Fluka (Neu-Ulm), Merck 
(Darmstadt), Roche (Mannheim), GERBU (Gaiberg), Serva (Heidelberg), Invitrogen 
(Karlsruhe), Qiagen (Hilden), Roth (Karlsruhe), Serva (Heidelberg), Sigma-Aldrich 
(Deisenhofen) and Jena Bioscience (Jena). 
Protein Standard 
SDS-6 97 / 66 / 45 / 30 / 20 / 14  kDa Amersham (Freiburg) 
DNA Standard 
GeneRulerTM Fermentas (St. Leon-Rot) 
Chromatography Columns and Material 
Hi-Load™ Superdex S75/S200 GE-Healthcare (Freiburg) 
HiTrap Chelating HP  GE-Healthcare (Freiburg) 
Synthesized Chemicals 
NBD-FPP 
Ser-Cys-Ser-Cys(GG) 
Ser-Cys(GG)-Ser-Cys 
Ser-Cys(GG)-Ser-Cys(GG) 
Synthesized und provide by Prof. 
Waldmann’s group with high purity 
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RabGGTase inhibitors 
MT650 
MT670 
KT90102 
BMS3 
Synthesized und provide by Prof. 
Waldmann’s group with high purity 
Psoromic acid Indofine Chemical company(Hillsborough)
Vectors 
pET27b(+) Novagen 
pET28a Novagen 
pET30a Novagen 
pGATEV Department III / AG Alexandrov 
Oligonucleotide primers 
All Oligonucleotide primers were purchased from Sigma-Aldrich (Deisenhofen) or MWG-
Biotech (Ebersberg). 
Primer 1 5`-CAGCAAGTATATAGCATGGCCTTT-3´ 
Primer 2 5`-GGTCGACGAATTCTCAAGCGTACTCCATCTTGAGAACAC-3´ 
Primer 3 5`-GGTTCTATCACCGCTGGCTCCTGGGTGCCGGTTCCGGCAGGTGT 
GAGCTGTCAGTGGAAAAG-3´ 
Primer 4 5`-GCTAGTTATTGCTCAGCGG-3´ 
Primer 5 5`-GGAGATATACCATGGCTTCTTCGAGTTCCTTCACCTATTATTG-3´ 
Primer 6 5`-GTTTGATCTCGAGTCATTCGCATTCCTCAAAGCCTGGGAC-3´ 
Primer 7 5`- CCCGTTTGATCTCGAGTCACTTCTGCAGAAAGTGTGTGGTGG-3´ 
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Primer 8 5`-CGATGGGTATCCATGGAGAATCTTTATTTTCAGGGGTTTCT 
GAGCCTGGACTCGCCCAC -3´ 
Primer 9 5`-GCCCGGATCCCTCGATCATACACTCGCCGGTATGTCACTTTC-3´ 
Enzymes 
Restriction enzymes New England Biolabs (Beverly) 
Restriction enzymes Fermentas (St. Leon-Rot) 
High Fidelity Expand polymerase Roche (Mannheim) 
T4-DNA Ligase New England Biolabs (Beverly) 
TEV protease Purified by AG Alexandrov 
Protease-inhibitors 
Phenylmethylsulfonyl fluoride (PMSF) Sigma (Deisenhofen) 
3.1.4 Kits 
Plasmid Mini-prep Kit PeQLab (Erlangen) 
Plasmid Gel Extraction Kit PeQLab (Erlangen) 
Cycle-Pure kit PeQLab (Erlangen) 
BigDyeDeoxy Terminator cycle sequencing 
Kit 
Applied Biosystems (Weiterstadt) 
Nextal screens Qiagen (Hilden) 
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3.1.5 Equipments 
ABI PRISM 3700 DNA Analyzer  Applied Biosystems (Langen) 
Analytical balance Sartorius (Göttingen) 
Benchtop Centrifuge, Eppendorf 5415C/D Eppendorf (Cologne) 
Benchtop Centrifuge, Avanti J20-XP Beckman (München) 
Bio-imaging System FLA-5000 FujiFilm (Germany) 
Biorad Mini-Protean II system BioRad (München) 
Dialysis tube Schleicher and Schuell (Dassel) 
Electroporation cuvette BioRad (München) 
Finnigan LCQ Advantage Max Thermo Electron Corporation (Dreieich) 
Formulatrix The Scripps Research institute (USA) 
FPLC Äkta Prime Amersham Pharmacia (Freiburg) 
FPLC Pharmacia Biotech GradiFrac GE Healthcare (Uppsala) 
Infors-HT Shakers Infors AG (Bottmingen) 
Leica MZ16/M165C Leica Microsystems (Wetzlar) 
Magnetic Stirrer RCT basic IKA Labortechnik 
MALDI-TOF-MS Applied Biosystems (USA) 
METTLER PM 480 Delta Range Mettler-Toledo-GmbH (Giessen) 
Microbiological Incubator WTC binder (Tuttlingen) 
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Microfluidizer Microfluidics Corporation 
MJ Research PTC-200 MJ Reasearch (Watertown, USA) 
Mosquito Pipetting Station TTP Labtech (UK) 
Nanodrop Spectrophotometer ND-1000 PeQLab (Erlangen) 
Olympus CX40 Olympus Optical Co., LTD. (Japan) 
pH-Meter 761 Calimatic Knick (Berlin) 
Rigaku MicroMaxTM-007HF Rigaku (UK) 
Rotors (JA 10-17, 30.50) Beckman (München) 
Spectro Fluorimeter FluoroMax 3 Spex Instruments Inc. (Edison, USA) 
Thermomixer Comfort Eppendorf (Hamburg) 
Ultracentrifuge, Beckman Optima L-70K Beckman (München) 
UV/VIS-Spectrometer DU 640 Beckman Coulter (USA) 
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3.2 Molecular biological methods  
3.2.1 Agarose gel electrophoresis  
Agarose gels were prepared and run according to standard procedures177. Agarose gel 
electrophoresis was used for analytical and preparative separation of DNA fragments. The 
method is based on the migration of the negatively charged DNA towards the anode in an 
electric field. The rate of migration of a DNA fragment through the agarose gel is inversely 
proportional to the logarithm (log10) of the number of base pairs. DNA bands were visualized 
by staining with the intercalating fluorescent dye Ethidium bromide and subsequent 
illumination under UV light. A DNA-molecular weight standard GeneRulerTM (Fermentas, 
St. Leon-Rot) was used to determine the DNA-fragment size. To cast the gel, 0.8 to 2% (w/v) 
agarose was melted in TAE buffer (0.2 M Tris, 5 mM EDTA, pH adjusted to 8 with acetic 
acid) and supplemented with 0.5 µg/ml Ethidium bromide and poured into a casting tray of 
the desired size. The gel was placed in an electrophoresis tank and submerged in TAE buffer. 
The DNA probes were mixed with 1/2th volume equivalent DNA loading buffer and the gels 
were run at 12 V/cm. 
3.2.2 Preparation of plasmid DNA 
Plasmid DNA was isolated from bacteria cultures by alkaline lysis of the bacterial cells using 
the plasmid Mini-prep Kit (peQLab Biotechnology GmbH) according to the protocols of 
manufacturer. 
To amplify the plasmid of interest in vivo, a small culture (10 ml) of bacteria (E. coli XL1 
Blue) was incubated with the appropriate antibiotic(s). The bacteria were harvested by 
centrifugation at 5000×g for 5 min and lysed by alkaline/SDS treatment. Chromosomal DNA, 
lipids and protein were precipitated and subsequently removed by centrifugation for 10 
minutes at 5000×g while the plasmid DNA was left in supernatant. The supernatant was 
filtrated through the spin column by centrifugation at 5000×g for 1 minute, followed by a 
washing step. Plasmid DNA was eluted using 50 µl sterile buffer (10mM TrisHCl pH 8.0) or 
deionized water. 
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3.2.3 Polymerase chain reaction (PCR)  
Amplification of DNA fragments was carried out using High Fidelity Expand Polymerase mix 
from Roche (Mannheim) according to standard procedures177;178. 
In brief, a 50 µl reaction mixture contained 1 – 10 ng of template DNA, 10 pM of upstream 
and downstream primers, 100 µM of dNTP mix, 2 – 4 units of High Fidelity Expand 
Polymerase mix from Roche (Mannheim) as well as the corresponding reaction buffer. The 
PCR-reaction was performed with a MJ Research PTC-200. Firstly, a denaturation step was 
performed for 1 min at 96 °C, followed by annealing for 30 sec at 55 – 65 °C depending on 
primer length and GC content. The extension step occurred at 72 °C for 2 – 3 min, depending 
on the length of the amplificated DNA fragment. In general, ca. 20 cycles were performed for 
amplification. Prior to further use, the salts in the reaction buffer were removed from the PCR 
reaction mixture using the Cycle-Pure Kit from PeQLab (Erlangen). 
3.2.4 DNA digestion  
DNA was digested using restriction enzymes and buffers from New England Biolabs 
(Beverly) or Fermentas (St. Leon-Rot) according to the protocols of manufacturer. 
The reaction mixture was incubated at the appropriate temperature and stopped by addition of 
DNA loading buffer after 1-2 h. The digested fragments were separated using agarose gel 
electrophoresis (see 3.2.1), which was followed by isolation (see 3.2.2) using the Gel 
Extraction Kit from PeQLab (Erlangen). 
3.2.5 Ligation  
For ligation ca. 100 ng of linearised vector was mixed with a five fold molar excess of insert 
DNA in reaction buffer using 10U T4-DNA ligase from New England Biolabs (Beverly) for 1 
– 2 h at 25 °C. 
3.2.6 Preparation of competent cells  
Competent expression (E. coli BL21 CodonPlus (DE3) RIL) or amplification (E. coli XL1 
Blue) cells were prepared as follows179: 5ml LB media was inoculated with a single colony of 
E. coli cells and incubated overnight at 37°C with shaking. 2.5 ml of this preculture was 
mixed with 250 ml LB media and grown to an optical density (OD600) of 0.8. The cells were 
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harvested by centrifugation for 10 minutes at 4°C and 2000×g. The pellet was washed with 
250 ml sterile H2O at 4°C, twice, and then mixed with 5 ml 10% (v/v) glycerol and 
centrifuged. The cell pellet was resuspended in approximately 2.5 ml GYT media (10% (v/v) 
glycerol, 0.125% (w/v) yeast extract, 0.25% (w/v) tryptone), aliquoted into 70 µl portions, 
flash frozen in liquid nitrogen and stored at -80°C. 
3.2.7 Transformation 
Electrotransformation was performed by applying a high voltage pulse using the E. coli Pulser 
from Biorad at 25 µF, 200 Ω and 2.5 kV177. 
Briefly, ca. 1 ng of ligated DNA fragment was mixed with the competent cell suspension in 
an electroporation cuvette on ice. After electrotransformation 1 ml of LB medium was added 
to the cell suspension and the culture incubated at 37 °C for 1h. Transformed cells were 
selected on agar plates containing the appropriate antibiotics.  
Ligated DNA was initially transformed in E. coli XL1 Blue, amplified and purified. The 
purified DNA was transformed in E. coli BL21 CodonPlus (DE3) RIL expression bacteria. 
3.2.8 Bacteria storage 
Glycerol stocks of transformed bacteria were made by adding an equivalent volume of 50% 
sterile glycerol to an overnight culture. Stocks were stored at -80 °C. 
3.2.9 DNA sequencing 
DNA sequencing was carried out according to180 using the BigDyeDesoxy terminator cycle 
sequencing kit (Applied Biosystems, Weiterstadt). A sequencing reaction mixture typically 
included 500 ng DNA, 4 µl terminator mix, 3.2 pmol sequencing primer in a volume of 10 µl. 
The sequencing PCR and DNA precipitation was carried out according to the protocols of 
manufacturer. Analysis of the sequencing products was performed on an ABI PRISM 3700 
DNA Analyzer (Applied Biosystems, Langen). 
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3.3 Expression and purification of proteins 
3.3.1 Growth and harvest of bacteria expressing prenyltransferases 
The α and β subunit of all prenytransferase variants were co-transformed into E.coli 
BL21CodonPlus(DE3) RIL cells. Cells were grown in a 37°C shaker at 200 rpm to an A600 
of 0.7-0.8.  The α subunits of FTase or RabGGTase were expressed as an N-terminal 6×His- 
and GST-Tag fusion protein and the β subunit of FTase or RabGGTase was expressed as the 
wild-type protein. Expression was induced with 100 µM isopropyl-β-D-thiogalactoside at 
37°C for FTase or 16°C for RabGGTase. After cell growth, the cells were pelleted at 5000×g 
for 15 min at 4°C; the cells were re-suspended in lysis buffer (50 mM Na2HPO4, pH 8.0, 0.3 
M NaCl and 2 mM β–mercaptoethanol) and were frozen at –80°C181. 
3.3.2 Nickel-NTA affinity chromatography 
The frozen cell pellet was resuspended in ice-cold lysis buffer (see 3.3.1) containing 1 mM 
protease inhibitor PMSF (phenylmethylsulfonyl fluoride). The cells were lysed using a 
microfluidizer (Microfluidics Corporation, USA) at a pressure of 950 kPa. The cell debris was 
removed from the lysate by centrifugation at 90,000×g at 4°C for 30 min and the supernatant 
was filtered. The lysate was loaded onto a Ni-NTA column (HiTrap Chelating HP, GE-
Healthcare) equilibrated in lysis buffer (see 3.3.1). After washing with 3-5 column volumes 
with lysis buffer (see 3.3.1), the bound N-terminal hexa-histidine and GST fusion α subunit in 
complex with β subunit were eluted on a 5-200 mM imidazole gradient. Protein containing 
fractions were identified by analysis on 15% SDS-PAGE and pooled. 
3.3.3 Removal of 6×His-tag and size exclusion chromatography 
To remove the histidine- and GST-Tags from the α subunit of FTase or RabGGTase, TEV 
protease was added at a 1:40 molar ratio and the sample was dialyzed against 25 mM 
Na2HPO4, pH 8.0, 1 mM EDTA and 2 mM β–mercaptoethanol at 4°C. The progression of the 
cleavage reaction was determined by SDS-PAGE. TEV protease and 6×His-GST-Tag were 
removed by passing the dialysed sample over a Ni-NTA column (HiTrap Chelating HP, GE-
Healthcare). The flowthrough was concentrated and then loaded on a Superdex S200 size 
exclusion column (GE-Healthcare) pre-equilibrated with gel-filtration buffer (25 mM HEPES 
pH 7.2, 40 mM NaCl, 5 mM β-mercaptoethanol) as a further purification procedure to obtain 
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pure protein for crystallisation purposes. The fractions containing pure protein were identified 
using SDS-PAGE and pooled. 
3.3.4 Concentrating proteins by ultra-filtration  
The pooled pure fractions were concentrated to ca. 20 mg/ml by a centrifugal concentrator or 
Amicon chamber (Vivascience, Lincoln, USA) with a 30 kDa cut off filter by centrifugation 
at 3000×g at 4°C. Aliquots were flash-frozen in liquid nitrogen and were stored at –80° C.  
3.3.5 SDS-PAGE  
For the analysis of proteins, one-dimensional gel electrophoresis was carried out using 
denaturing 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) according to the 
standard protocol177. 
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3.4 Biochemical and biophysical methods  
3.4.1 Determination of protein concentration 
Protein concentrations were determined using the Biorad protein assay solution182. This 
solution was calibrated prior to use by bovine serum albumin (BSA). 
3.4.2 Fluorescence spectroscopy  
Fluorescence is highly sensitive to the environment around fluorophore, what makes it very 
valuable for kinetic and other investigations of molecular interactions. 
NBD-FPP is a fluorescent analogue of geranylgeranyl pyrophosphate that binds to 
RabGGTase competitively to its natural lipid substrate92;183. The fluorescent NBD fluorophore 
serves as a read-out for interactions between RabGGTase and isoprenoids, as well as between 
RabGGTase and mono- or di-prenylated Rab7 C-terminal peptides. 
To determine the affinities between RabGGTase and mono- or di-prenylated Rab7 C-terminal 
peptides, competitive titration125 was carried out using a Fluoromax 3 Spectro fluorimeter 
(SPEX instruments S.A., Inc., Edison, USA) in 0.4 x 1 cm2 cuvettes at 25°C. 200 nM NBD-
FPP was mixed with 1 µM prenylated peptide in 50 mM Hepes pH 7.2, 50 mM NaCl, 2 mM 
MgCl2, 5 mM DTE and 2% DMSO. The mixture was titrated with increasing concentrations 
of RabGGTase. NBD-FPP was excited at 487 nm and fluorescence was monitored at 550 nm. 
The decrease in fluorescence upon addition of protein was measured, and at each step the 
values were averaged after equilibrium. Kd-values were obtained by fitting data using the 
program Scientist 2.0 as described by Thoma et al. (2000). 
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3.5 Crystallographic methods 
3.5.1 Crystallisation  
Initial protein crystallisation is a trial-and-error procedure in which the protein is slowly 
precipitated from its solution. Usually, crystallogenesis falls into two separate phases. The 
first is the screening of crystallisation conditions to obtain the first crystalline material, the 
second is the optimising of the identified conditions to improve the size and quality of the 
crystal. The classical procedure for slowly precipitating proteins from solution to form a 
crystal is to gradually increase the level of saturation by addition of a precipitant. The typical 
precipitating agents include salts (such as ammonium sulphate), organic solvents (such as 
glycerol and methylpentanediol (MPD)), and highly soluble synthetic polymers (such as 
polyethylene glycol (PEG)). 
3.5.2 Crystallisation by vapour diffusion methods 
Vapour diffusion was first used for the crystallization of tRNA184 and now it is the most 
widely used method for protein crystallisation. A drop containing the protein to crystallise 
with buffer, precipitating agent with appropriate ions, is equilibrated against a reservoir of 
precipitating agent in a sealed container. Equilibration occurs by diffusion of water molecules 
until the vapour pressure in the drop equals that in the reservoir. During equilibration the 
concentration of all constituents in the drop increases, which in turns lead to nucleation in the 
drop. In this work, two variations of vapour-diffusion, ‘hanging drop’ and ‘sitting drop’ 
methods, are used. The details of protein crystallizations are described in the results and 
discussion (see 4.5 and 4.6). 
3.5.3 Co-crystallisation and crystal soaking  
Co-crystallisation and soaking are two common approaches used in seeking structures of 
proteins in complex with small molecules, such ligands and inhibitors. 
In the soaking approach, the compound is incubated with protein crystals, which have been 
crystallized in the absence of ligands or inhibitors. The soaked ligand or inhibitor is expected 
to diffuse into the crystals and to associate with their binding site of the protein, such as the 
active site of enzyme. Protein crystals typically have a high solvent content, ranging from 30 
to 80%185. This solvent forms channels through the crystals, typically from 20 to 100 Å in 
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diameter186, and allows the diffusion of small molecules. Ideally, the protein in the crystal 
should have sufficient freedom to undergo conformational changes induced by binding to the 
small molecules. 
In the co-crystallisation approach, the ligands or inhibitors are incubated with the protein prior 
to crystallisation and the complex is then crystallized. In some cases conditions for co-
crystallisation of a protein in complex with ligands or inhibitors may differ from that of the 
apoenzyme or of other compound complexes. 
3.5.4 Cryo-crystallography  
In many cases, protein crystals are prone to radiation damage over the time caused by the 
formation of solvent-derived free radicals in the crystals. Cryo-crystallography (at 100K) is a 
powerful means to overcome such hurdles, since the low temperatures can slow-down the 
process of radical formation by preventing the heating of the crystals when exposed to x-rays. 
Cryo-crystallography enables the measurement of a complete data set from a single crystal. In 
some cases it provides higher resolution than room temperature measurement, it is suggested 
that cooling may increase the internal order of the parts of the protein which are mobile at 
room temperature187. For cryo-crystallography, the crystals are transferred into a suitable 
cryo-protectant solution and mounted on a cryo-nylon loop. The crystals are then flash-frozen 
in liquid nitrogen. To prevent the formation of ice crystals, the cryo-protectants commonly 
contain appropriate concentrations of glycerol, ethelene glycol, MPD, PEGs or sugars. 
3.5.5 Data collection  
All cryoprotected crystals were first tested on an in-house source, which used a copper 
rotating X-ray anode with an Osmic mirror (λ = 1.5419 Å, 50 kV, 100 mA, 0.1 mm 
collimator). Usually, the final datasets were collected at beamline PXII at the Swiss Light 
Source, Villigen, Switzerland. Data processing, including indexing, integration and scaling, 
was carried out using the program XDS188. The quality of the datasets were validated based 
on the I/σ (signal to noise ratio) where generally a cut-off of 3 is widely accepted, and also by 
calculating Rsymm which compares symmetry related reflections according to Equation 1. 
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Equation 1 
h, k, l – indices of independent reflections with the average intensity <I>  
Ii– intensities of independent reflections. 
3.5.6 Matthews coefficient and solvent content analysis 
Based on the volume of the asymmetric unit and the molecular weight of the protein, the 
number of protein molecules present in a unit cell can be estimated189. The Matthew 
coefficient VM is described by Equation 2. 
ZMw
VVM ⋅=  Equation 2 
V – Volume of the asymmetric unit in Å3 
Mw – Molecular weight of the monomer in Dalton  
Z – Number of molecules in the asymmetric unit  
The average Matthew coefficient of a protein crystal is 2.5 Å3/Da which corresponds to a 
solvent content of 50%189. 
3.5.7 Phase determination 
During data collection, the intensities of waves scattered from planes (denoted by h, k and l) 
in the crystal are measured. To calculate the electron density at a position (xyz) in the unit cell 
of a crystal requires a summation over all the hkl planes, which is mathematically expressed 
in Equation 3. 
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Equation 3 
V – Volume of the unit cell  
αhkl – Phase associated with the structure factor amplitude │Fhkl│ 
Fhkl is a periodic function and possesses amplitude, frequency and phase (αhkl). This is 
diffracted and thus has the same frequency as that of the x-ray source. The amplitude of Fhkl is 
proportional to the square root of the reflection intensity (Ihkl) measured on the detector. 
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However, the phases are lost during measurement, as there is no formal relationship between 
amplitudes and phases. Thus phases can be not directly obtained from a single measurement 
of reflection intensities. The only relationship is via the molecular structure or electron 
density. Therefore, the values of phases can be evaluated, if there is some prior knowledge of 
the structure or electron density. This is the basis for all phasing methods (Table 3.1). A 
detailed description of phase problem is described elsewhere190. In this work molecular 
replacement (MR) has been used. 
Table 3.1: Different phasing methods, modified from Garry Taylor Acta Cryst. (2003). 
Phasing Method Necessary Prior Knowledge 
Direct methods 
Isomorphous replacement 
ρ≥0, discrete atoms 
Heavy-atom substructure 
Anomalous scattering Anomalous atom substructure 
Molecular replacement Homology model 
Density Modification (Phase Improvement) 
Solvent content, Phase extension, Non-
crystallographic symmetry etc. 
3.5.8 Phase determination using molecular replacement (MR) 
If a homology model is available, molecular replacement can be successfully employed to 
obtain phase information, as first described by Rossmann & Blow191. In this method, the 
values of phases for the unknown structure can be evaluated from the coordinates and the 
structure factor amplitudes (FCalc) of the known structure. In general the space group and the 
orientation of the unknown structure differ from those of the known structure, thereby the 
known structure as a search model is required to be reoriented in the new unit cell 
appropriately. This is achieved by comparing the Patterson functions, which are obtained 
from the structure factor amplitude (FObs) of the measured intensities and from the search 
model (FCalc)192;193. 
3.5.9 Refinement 
After obtaining proper phase information the initial structural model can be built. It contains 
errors that can be minimised through iterative model refinement. During refinement the 
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atomic coordinates of the current model were adjusted in order to minimise the difference 
between experimentally observed structure factor amplitudes (FObs) and those calculated from 
the model (FCalc). The quality of the model was evaluated using the crystallographic index ‘R-
factor’ and ‘R-free’. The R factor is described by equation 4. 
∑
∑ −
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hklF
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Equation 4 
However if the crystallographic data are over-weighted, the R-factor can be artificially 
lowered at the expense of the stereochemistry of the model. To overcome this over-fitting, 5% 
of the data (a test set of reflections ‘T’) are isolated from the remainder (the working set) and 
not used for the purposes of refinement194. The working set is used for the calculation of the 
R-factor as described by the equation 4, whereas the test set for the calculation of a new 
parameter, R-free, which is defined similarly to R factor. 
∑
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Equation 5 
The R-free parameter is a sensitive indicator of over-fitting. It is expected, that the value of 
the R-factor is slightly lower than that of the R-free. 
The program REFMAC5195 was used for refinement and the models were built and adjusted 
manually using the software COOT196. The model was validated by the program Procheck197. 
3.5.10 Representation of structures 
All figures were generated using the program PYMOL (www.pymol.org, DeLano Scientific 
LLC) and the final figures were prepared with the help of Photoshop (Adobe Corporation) or 
Canvas (ACD System Inc.). 
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4 Results and discussions 
Section I 
Engineering, cloning and purification 
of RabGGTase and FTase from E. coli 
4.1 Engineering of rat RabGGTase mutants 
The structural analysis of RabGGTase is hampered by difficulties in reliably obtaining well 
diffracting crystals. Although RabGGTase has previously been crystallized in the apo form as 
well as in complex with REP-1 and a farnesyl moiety, in both cases the search for well 
diffracting crystals required considerable effort90;93. In contrast, both GGTase-I and FTase 
could be crystallized and a large number of structures in complex with substrate analogues 
and inhibitors are known88;89;198. Comparing the RabGGTase structure to FTase and GGTase-
I, the most striking difference is the presence of two additional domains in the α subunit of 
RabGGTase, the LRR (Leucine-rich repeat) domain and the IG (Ig-like domain) domain 
(Figure 4.1). The LRR and IG domains of RabGGTase do not make contacts with the β 
subunit. Since the LRR (residue 442 to residue 567) and IG (residue 238 to residue 352) 
domains of mammalian RabGGTase are not involved in its catalytic activity93, we decided to 
engineer versions of the enzyme in which these domains were deleted. Mutant variants of the 
α subunit gene lacking sequences for either the LRR or IG domain or both were created. The 
overall shape of the RabGGTase mutant lacking both LRR and IG domains is expected to be 
similar to that of FTase or GGTase-I, which could make it more amenable to crystallisation 
than the parental enzyme. While deletion of the C-terminally located LRR domain is trivial 
from the protein engineering point of view, removing the IG domain inserted into the middle 
of the molecule is less obvious. A linker Ala-Gly-Ser-Gly connecting helices 11 and 12 
(residues 237 and 353) was designed based on the alignment of yeast and mammalian 
RabGGTase.  
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Figure 4.1: Engineering of rat RabGGTase. Structure of wild type mammalian RabGGTase. The α 
subunit is displayed in ribbon representation and domains are coloured while the β subunit is shown as a 
molecular surface. 
The vectors for E. coli expression of mutants of the α subunit of RabGGTase were 
constructed as follows: pGATEV-RabGGTase_αΔLLR was constructed by a PCR 
amplification of the RabGGTase α subunit gene with the direct primer 1 (see 3.1.3) annealing 
to GST tag and the reverse primer 2 (see 3.1.3) using pGATEV-RabGGTase_α as a 
template181. The resulting PCR fragment was digested with NdeI and EcoRI and cloned into 
the pGATEV vector pre-digested with the same enzymes. 
pGATEV-RabGGTase_αΔIG was constructed by a two step PCR. In the first step a 5’ 
fragment of the α subunit was PCR amplified using the above described template with 
specific forward primer 3 and reverse primer 4 (see 3.1.3) annealing to the T7 terminator. The 
resulting 600bp product was gel purified and used in the second round of PCR as a reverse 
primer in combination with the direct primer 1 (see 3.1.3) annealing to GST tag. Cloning into 
the pGATEV vector was performed as described above.  
pGATEV-RabGGTase_αΔLLRΔIG was obtained as described for pGATEV-
RabGGTase_αΔLLR but using pGATEV-RabGGTase_αΔIG as a template for the PCR 
reaction. 
In all cases the integrity of open reading frame was determined by sequencing. 
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4.2 Purification of engineered RabGGTases from E. coli 
Genes for mutant α and wild type β subunits of RabGGTase were co-expressed in E. coli as 
described in Material and Methods (see 3.3)181 and analyzed for expression level and 
solubility. Soluble recombinant proteins were observed in the case of the α subunit lacking 
either the LRR domain or both LRR and IG domains.  In both cases the α/β-heterodimer 
remained stable throughout purification on Ni-NTA and gel filtration columns and could be 
purified to near homogeneity. As can be see in Figure 4.2, in both mutants the subunits were 
present at 1:1 stoichiometry, indicating that engineering does not affect the structural integrity 
of the α subunit (Figure 4.2). 
 
Figure 4.2: Purification of wild type and mutants of rat RabGGTase. SDS-PAGE analysis of 
recombinantely produced wild type and deletion mutants of RabGGTase. 
To confirm that the obtained mutants were catalytically active, a recently described 
fluorescent in vitro Rab prenylation assay183 was performed by Yaowen Wu. Briefly, in the in 
vitro prenylation assay 4 μM Rab7, 4 μM REP-1, 4 μM wild type or mutant RabGGTase and 
40 μM NBD-FPP were mixed in a buffer containing 50 mM Hepes pH 7.2, 50 mM NaCl, 2 
mM MgCl2 and 5 mM DTE at room temperature. In control reactions, REP-1 was omitted. 
The progression of the reaction was monitored by changes in NBD fluorescence. In summary, 
both mutants were able to prenylate Rab7 with an efficiency comparable to that of wild type 
enzyme199 (Figure 4.3). This directly confirms the earlier proposal that IG and LRR domains 
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of mammalian RabGGTase are not involved in the prenylation reaction and perform an as yet 
unidentified function92. 
 
Figure 4.3: Functional analysis of wild type and mutants of rat RabGGTase199. In the in vitro prenylation 
Rab7 was mixed with wild type and mutants of RabGGTase using NBD-FPP as a substrate. Incorporation 
of NBD-F into Rab7 was measured as described in Wu, 2006 1640 and plotted against time. Open circles – 
RabGGTase_αΔLLRΔIG enzyme, open triangles RabGGTase_αΔIG, filled triangles - wild type enzyme. 
4.3 Engineering of rat FTase mutants 
Recombinant rat FTase obtained from the insect cell (Sf9)/baculovirus expression 
system95;200, an expression system with relatively low FTase levels, has been successfully 
utilized to solve the FTase crystal structure91;198. In this crystal form, the enzyme active site is 
partially occupied by C-terminal residues of the β subunit from an adjacent molecule in the 
crystal lattice. This steric obstruction could hinder enzyme ligands from binding to the active 
site, cause local conformational changes and substantially reduce crystal diffraction 
resolution96. Recently, Weber’s group crystallized a β subunit C-terminal truncation mutant 
and solved its structure at high resolution201. The new FTase crystal form contained an open 
active site. The FTase mutant was obtained by recombinant expression in E. coli. It was 
truncated at the C-terminus of β subunit by 10 amino acid residues and contained an extra 20 
amino acid residues including a His-tag at the N-terminus of the α subunit of FTase. 
To facilitate the purification of large quantities of protein for crystallographic and 
thermodynamic studies of FTase:inhibitor interactions and provide a system for the rapid 
production of site-directed mutants, an E. coli expression system for FTase was used in our 
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research. Analysis of the FTase crystal structure91;201 revealed that the β subunit C-terminal 
tail, primarily the last five amino acid residues, interacts with the active site through a 
combination of hydrogen bonds and hydrophobic interactions (Figure 4.4). The active site 
residues involved in the binding were mainly from the β subunit, including residues Trp102β, 
His248β, Lya264β, Arg291β, Tyr300β, Cys345β, Ser357β and two α subunit residues 
Tyr166α and Asp196α. Based on this analysis, two β subunit C-terminal truncation mutants, 
Δ10 and Δ19, were designed to eliminate the C-terminal tail from the active site. The Δ10 
truncation would remove the majority of the interaction, while the Δ19 would further 
eliminate the binding residues of the C-terminal tail. 
 
Figure 4.4: Hydrogen bonding and hydrophobic interactions between the β subunit C-terminal tail and 
the FTase active site residues mapped from the FTase structure (PDB code: 1FT1)91. 
The vectors for E. coli expression of β subunit mutants of FTase were constructed as follows: 
pET27b(+) βCΔ10 was constructed by a PCR amplification of the FTase  β subunit gene with 
the forward primer 5 and the reverse primer 6 (see 3.1.3) using pET28a-FTase_β as a 
template. The resulting PCR fragment was digested with NcoI and XhoI and cloned into the 
pET27b(+) vector pre-digested with the same enzymes. 
The vectors pET27b(+) βCΔ19 was obtained as described for pET27b(+) βCΔ10 but using the 
forward primer 5 and the reverse primer 7 (see 3.1.3) for the PCR reaction. 
In addition, the N-terminal domain (~50 amino acids) of α subunit is disordered in FTase. To 
improve the chance of FTase crystallisation an α-subunit N-terminal truncation mutant (Δ50) 
was designed to eliminate the flexible N-terminal tail. 
The vectors for E. coli expression of mutant of α subunit of FTase were constructed as 
follows: pGATEV αNΔ50 was constructed by a PCR amplification of the FTase α subunit 
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gene with the forward primer 8 and the reverse primer 9 (see 3.1.3) using pGATEV-FTase_α 
as a template. The resulting PCR fragment was digested with NcoI and XhoI and cloned into 
the pGATEV vector pre-digested with the same enzymes. 
In all cases the integrity of open reading frame was determined by sequencing. 
4.4 Purification of wild-type and engineered FTases from E. 
coli 
Genes for α and β subunits (wild-type or mutant) of FTase were co-expressed in E. coli as 
described in Material and Methods (3.3)181. Soluble recombinant protein could be obtained 
and the α/β-heterodimer remained stable throughout purification on Ni-NTA and gel filtration 
columns and could be purified to near homogeneity in all cases. In all mutants the subunits 
were present in 1:1 stoichiometry indicating that engineering does not affect the structural 
integrity of the heterodimer (Figure 4.5).  
 
Figure 4.5: Purification of wild type and mutants of rat FTase. SDS-PAGE analysis of recombinantely 
produced wild type and truncation mutants of FTase. 
To confirm that the obtained variants of FTase were catalytically active, a recently described 
fluorescent in vitro prenylation assay202;203 was performed. In this assay Ypt7 was used and 
expressed in E. coli with the C-terminal extension TKCVIM, derived from a mammalian K-
Ras protein. Briefly, in the prenylation reaction 15 μM Ypt7_TKCVIM, 3 μM variants of 
FTase and 45 μM fluorescent isoprenoid substrates NBD-GPP were mixed in a buffer 
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containing 50 mM Hepes pH 7.2, 50 mM NaCl, 2 mM MgCl2 and 5 mM DTE. Control 
samples were supplemented with an excess of FPP (225 µM) that would compete with the 
fluorescent analogues and thus yield non-fluorescently prenylated Ypt7_TKCVIM. The 
reaction proceeded for 2 h at room temperature and was quenched by addition of SDS-PAGE 
sample buffer, after which the samples were resolved on a 15% SDS-PAGE gel and scanned 
for fluorescence using a fluorescent image reader followed by Coomassie blue staining. 
 
Figure 4.6: Functional analysis of wild type and mutants of rat FTase. SDS-PAGE gels of the fluorescently 
labeled Ypt7_TKCVIM proteins after prenylation with NBD-GPP mediated by variants of FTase. The 
control reactions were supplemented with a 5-fold excess of FPP over the fluorescent isoprenoid. Upper 
panels represent the fluorescent scans of the gels, while the lower panels show the same gels stained with 
Coomassie blue. Under these conditions incubation of all variants of FTase with protein substrate 
Ypt7_TKCVIM led to emergence of fluorescent bands with comparable intensities corresponding to 
prenylated Ypt7_TKCVIM. No fluorescent product was generated when FTase was omitted. 
As can be seen in Figure 4.6 under these conditions incubation of all variants of FTase with 
protein substrate Ypt7_TKCVIM led to emergence of fluorescent bands with comparable 
intensities corresponding to prenylated Ypt7_TKCVIM. No fluorescent product was 
generated when FTase was omitted (Figure 4.6). In summary, all mutants were able to 
prenylate Ypt7_TKCVIM with an efficiency comparable to that of wild type enzyme. 
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Section II 
Crystallisation and structural determination 
of protein prenyltransferases 
4.5 Crystallisation and structural determination of 
RabGGTase_αΔLRRΔIG mutant 
Initial crystallisation conditions were found at 20 °C using 100 nl of the Classics, PEG, PEG 
II, JCSG, PACT and protein complexes suites from Qiagen plus 100 nl of protein solution of 
RabGGTase mutants (RabGGTase_αΔLRRΔIG or RabGGTase_αΔLRR) in sitting drops, set 
up against a 50 µl reservoir using a Mosquito nanolitre dispensing robot (Molecular 
Dimensions Limited). Crystals were observed only with the enzyme in which the α subunit 
lacked both LRR and IG domains (Figure 4.7, left). 
  
Figure 4.7: Crystals of the RabGGTase_αΔLRRΔIG mutant obtained during the initial crystallisation 
screening (left) and after optimization of crystallisation condition (right). 
Promising conditions were optimized with respect to precipitant composition, pH, 
temperature and protein concentration, changing the setup to hanging drops, prepared by 
mixing 1 µl of protein solution with 1 µl of precipitant mixture. The crystals for data 
collection were obtained at 12°C with a reservoir consisting of 14% (w/v) PEG 3350, 0.2 M 
CaAc2, 0.1 M HEPES pH 7.2. The protein was supplied at 14 mg/ml in a buffer containing 25 
mM HEPES pH 7.2, 40 mM NaCl, 5 mM β-mercaptoethanol. The observed crystals formed in 
a cubic shape and grew to a size of approximately 60*60*60 µm within 1 day (Figure 4.7, 
right). 
Results and discussions
 
 
 
50
Prior to flash-cooling in liquid nitrogen, the crystals were briefly washed in 20% (w/v) PEG 
3350, 5% (v/v) glycerol, 0.2 M CaAc2, 0.1 M HEPES pH 7.2. Diffraction data were collected 
at 100 K, at station X10SA of the Swiss Light Source (SLS Villigen, Switzerland). The data 
were processed with XDS188. The crystals belong to the orthorhombic space group P212121, 
contain one RabGGTase_αΔLRRΔIG complex in the asymmetric unit, and diffract to 1.8 Å 
resolution. 
Initial phases were determined by molecular replacement with PHASER204 of the CCP4 
suite205, using coordinates of RabGGTase in the RabGGTase:REP-1 complex (PDB code 
1LTX)93 from which the IG and LRR domains had been deleted. The model was then 
corrected by alternating rounds of refinement in REFMAC5195 and manual adjustment in 
COOT196. Full data collection and refinement statistics are given in Table 4.2. Coordinates 
and structure factors have been deposited in the Protein Data Bank PDB206 with entry code 
xxxx. 
The structure of the RabGGTase mutant was determined to 1.8 Å resolution by molecular 
replacement. The final model of RabGGTase_αΔLRRΔIG contains 394 water molecules, one 
Zn2+ ion and two Ca2+ ions. The structure is refined to an R-factor of 18.5 % and Rfree of 21.8 
%. The model of the RabGGTase mutant contains an α/β heterodimer in the asymmetric unit. 
Of the total residues for the RabGGTase mutant structure, 90.8 % lie in the most favoured 
region of the Ramachandran plot (PROCHECK197). Most of the residues with poorer electron 
density are located in the additionally allowed regions, with no residue in the disallowed 
region. 
Figure 4.8 A shows a cartoon representation of the engineered molecule, which bears the 
typical hallmarks of a prenyltransferase: a crescent-shaped α-subunit formed by seven 
successive pairs of helical hairpins wrapped around the β subunit. The β subunit folds into an 
α-α barrel consisting of six core and six peripheral helices. 
As expected the overall structure of the engineered enzyme changed very little compared to 
the wild type protein with an overall Cα RMS-deviation of 0.85 Å for 602 residues (Figure 
4.8 B). Most of the changes are represented by shifts in the position of α-helices in the α 
subunit while the β subunit is essentially unchanged with a Cα RMS-deviation of 0.35 Å. 
Electron density is missing for the flexible 18 N-terminal amino acids and for the loop region 
between helices 9 and 10. The engineered link between helices 11 and 10, on the other hand, 
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is visible in the electron density (Figure 4.8 A), indicating that the chosen length and 
sequence were appropriate to create a defined structure. 
Similar to the native enzyme the mutant contains the catalytic Zn2+ ion at the top of the active 
site funnel in the β subunit. The Zn2+ ion is coordinated by Asp238β, Cys240β and His290β 
(Figure 4.8 A) in a fashion identical to that observed in wild type RabGGTase. 
 
Figure 4.8: Overall structure of RabGGTase_αΔLRRΔIG mutant and Zn2+ binding site. (A) The α (green) 
and β (gray) subunits are displayed in cartoon and Zn2+ (yellow) in sphere representation. The designed 
connection loop Ala-Gly-Ser-Gly is coloured in red. The residues coordinated with Zn2+ (D238β, C240β 
and H290β) are displayed in stick representation. (B) Superposition of wild type RabGGTase (green, PDB 
code: 1DCE)90 and the RabGGTase_αΔLRRΔIG mutant (magenta) demonstrates the structural 
similarity. The α and β subunits of the both proteins are displayed in cartoon and Zn2+ in sphere 
representation. 
4.6 Crystallisation and structural determination of FTase 
mutants 
Initial crystallisation screening experiments were performed as described above (4.5) using 
wild type and engineered FTase from E. coli. A number of distinct crystal shapes was 
observed using the different FTase mutants in various conditions. After optimization of the 
crystallisation conditions, crystals of sufficient size could be obtained (Figure 4.9). 
Diffraction to a high resolution shell, however, was observed only in the case of the construct 
FTase_α_βCΔ10 (lacking 10 amino acids at the C-terminus of β subunit). 
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Figure 4.9: Crystals of FTase wt and mutants obtained during initial crystallisation screening and after 
optimization of crystallisation conditions. 
High resolution crystals (images numbered 6 in Figure 4.9) of FTase_α_βCΔ10 were obtained 
at 20°C with the hanging drops method by mixing 1 µl of protein solution with 1 µl of 
precipitant mixture consisting of 20% (w/v) PEG 4000, 0.2 M MgCl2, 0.1 M Tris pH 7.5. The 
protein was supplied at 10 mg/ml in a buffer containing 25 mM HEPES pH 7.2, 40 mM NaCl, 
5 mM β-mercaptoethanol. The crystals (6 in Figure 4.9) had a hexagonal shape and grew to a 
size of approximately 60*60*20 µm within 1 week. 
Prior to flash-freezing in liquid nitrogen, the crystals were washed in 20% (w/v) PEG 3350, 
5% (v/v) glycerol, 0.2 M MgCl2, 0.1 M Tris pH 7.5. Data sets were collected at 100 K, at 
station X10SA of the Swiss Light Source. The data were processed as described above (4.5). 
The crystals belong to the hexagonal space group P61, contain one FTase_α_βCΔ10 complex 
in the asymmetric unit and diffract to 2.8 Å resolution.  
Initial phases were determined by molecular replacement with PHASER of the CCP4 suite, 
using coordinates of FTase (PDB code: 1FT1)91 without 10 amino acids at the C-terminus of 
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the β subunit as search model. The model was then corrected by alternating rounds of 
refinement in REFMAC5 and manual adjustment in COOT. Full data collection and 
refinement statistics are given in Table 4.2. 
The structure of the FTase_α_βCΔ10 mutant was determined at 2.8 Å resolution. The final 
model of the FTase_α_βCΔ10 mutant structure contains 54 water molecules and one Zn2+ ion. 
And the structure is refined to an R-factor of 17.7 % and Rfree of 23.2 %. The model of the 
FTase mutant contains one α/β heterodimer in the asymmetric unit. Of the total residues for 
the FTase mutant structure, 86.5 % lie in the most favoured region of the Ramachandran plot 
(PROCHECK). Most of the residues with poorer electron density are located in the 
additionally allowed regions. 
The secondary structure of both the α and β subunits is largely composed of α helices (Figure 
4.10 left). Helices of the α subunit are folded into seven successive pairs that form a series of 
right-handed antiparallel coiled coils. These “helical hairpins” are arranged in a double-
layered, right-handed superhelix resulting in a crescent shaped subunit that envelops part of 
the β subunit. Twelve α helices of the β subunit are folded into an α-α barrel (Figure 4.10 
left). A core of six parallel helices forms the inner portion of the barrel. The other six 
additional helices interconnect the inner core of helices and form the outside of the helical 
barrel. The N-terminal domain (~50 amino acids) is disordered in the structure of the FTase 
mutant (similar with wild type FTase). In addition, two C-terminal amino acids of the β 
subunit are invisible in the structure.  
As expected the structure of the engineered enzyme contains an open active site and is almost 
identical with the structure of wild type FTase (PDB code: 1FT1)91 expressed in insect cells, 
with a Cα RMS-deviation of 0.65 Å for 709 residues (Figure 4.10 right). The catalytic zinc ion 
is located at the top of the active site funnel in the β subunit, which is coordinated by residues 
Asp297β, Cys299β and His362β (Figure 4.10 left). 
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Figure 4.10: Overall structure of FTase_α_βCΔ10 mutant and Zn2+ binding site. (A) The α (green) and β 
(gray) subunits are displayed in cartoon and Zn2+ (yellow) in sphere representation. The residues 
coordinated with Zn2+ (D297β, C299β and H362β) are displayed in stick representation. (B) Superposition 
of wild type FTase (green, PDB code: 1FT1)91 and the FTase_α_βCΔ10 mutant (magenta) demonstrates 
the structural similarity. The α and β subunits of both proteins are displayed in cartoon and Zn2+ in 
sphere representation. 
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Section III 
Structural Analysis of the protein prenyltransferase 
bound to phosphoisoprenoids 
4.7 Structure of RabGGTase_αΔLRRΔIG in complex with its 
lipid substrate GGPP 
The availability of a RabGGTase construct displaying robust crystallisation behavior and near 
native biochemical properties prompted us to attempt to solve the structure of RabGGTase 
with its native substrate geranylgeranyl pyrophosphate (GGPP). The availability of such a 
structure would complete the picture of enzyme:substrate complexes for the protein 
prenyltransferase family and give mechanistic insights into lipid substrate specificity of  
protein prenyltransferases. 
The co-crystallisation approach (3.5.3) was used to obtain enzyme:isoprenoid complex 
structures, which were prepared as follows. 1 µl of 2 mM isoprenoid GGPP in methanol were 
applied to a glass cover slip. After evaporation of the organic solvent, 1 µl of protein solution 
(12 mg/ml protein in 40 mM NaCl, 5 mM β-mercaptoethanol, 25 mM HEPES pH 7.2) and 1 
µl of reservoir containing 14% (w/v) PEG3350, 0.2 M CaAc2, 0.1 M HEPES pH 7.2 were 
added. The drop was equilibrated in a hanging drop setup at 12°C against 500 µl reservoir. 
The crystals had a rectangular shape and grew to a size of approximately 40*40*100 µm 
within 1 day (Figure 4.11). The rectangular shape of complex crystals is different from the 
cubic shape observed in the case of the apo enzyme. 
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Figure 4.11: Crystals of RabGGTase_αΔLRRΔIG mutant in complex with GGPP obtained by a co-
crystallisation approach. 
Cryoprotection was achieved by washing crystals briefly in 20% (w/v) PEG3350, 5% (v/v) 
glycerol, 0.2 M CaAc2, 0.1 M HEPES pH 7.2 supplemented with 2 mM GGPP prior to flash-
cooling in liquid nitrogen. Diffraction data were collected at 100 K on beamline X10SA of the 
Swiss Light Source (Villigen, Switzerland) and processed with the XDS package. The crystals 
belong to orthorhombic space group P212121 and contain one copy of the 
RabGGTase_αΔLLRΔIG:GGPP complex in the asymmetric unit.  
The structures were solved by molecular replacement with PHASER software using the apo-
form of RabGGTase_αΔLRRΔIG as a search model. The structures were refined in 
REFMAC5 and COOT. The complex structure was determined to 1.85 Å resolution. Initial 
difference density electron maps (fofc-map)o showed strong positive density in the 
hydrophobic cavity of the α-α barrel of the β subunit (Figure 4.12). 
 
Figure 4.12: Difference electron density of GGPP displayed at 2.5 σ. The electron density (fofc-map) was 
calculated before incorporation of the ligand into the model. The truncated RabGGTase and GGPP 
molecule are displayed in ribbon and stick, respectively. 
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The isoprenoid substrate GGPP was added in the final rounds of refinement, using a restraints 
library generated with PRODRG207. Full data collection and refinement statistics are 
summarized in Table 4.2. Structure factors and coordinates will be deposited in the Protein 
Data Bank with entry code xxxx (RabGGTase_αΔLRRΔIG:GGPP). 
The quality of the final electron density map together with a comparison of the refined 
temperature factors of GGPP (~40 Å2) and the surrounding protein residues (~35 Å2) suggest 
that the occupancy of GGPP is approximately 85%.  
The final model of the RabGGTase_αΔLRRΔIG:GGPP complex contains 127 water 
molecules, one GGPP molecule, one Zn2+ ion and two Ca2+ ions. The structure is refined to an 
R-factor of 21.3 % and Rfree of 25.0 %. The model of the complex contains one α/β 
heterodimer in the asymmetric unit. 91.0 % of all residues of the complex structure lie in the 
most favoured region of the Ramachandran plot (PROCHECK). Most of the residues with 
poorer electron density are located in the additionally allowed regions. 
Similar to structures of other prenyltransferases the hydrophobic tail of GGPP is held in the 
hydrophobic binding cleft formed by conserved predominantly aromatic residues Tyr51β, 
Trp52β, Phe147β, Tyr195β, Tyr241β, Trp243β, Trp244β, Phe289β,  Phe293β, Phe143α and 
Tyr107α (Figure 4.13 A). Binding of GGPP to RabGGTase leads to several minor changes in 
the structure of the active site mostly involving rotation or displacement of side chains of the 
hydrophobic residues Phe293β, Tyr241β, Trp244β and Tyr195β (Figure 4.13 B). 
 
 
 
 
 
Results and discussions
 
 
 
58
 
 
Figure 4.13: Structure of RabGGTase_αΔLLRΔIG mutant in complex with GGPP. (A) The α (green) and 
β (gray) subunits are displayed in cartoon forms. The GGPP molecule (magenta) and the residues (Y51β, 
W52β, F147β, Y195β, Y241β, W243β, W244β, F289β, F293β, F143α, Y107α), which line along the central 
cavity, are displayed in stick representation. The Zn2+ ion and water molecule are shown as yellow and red 
balls, respectively. (B) Superposition of apo RabGGTase mutant (gray) and its complex with GGPP 
(green) demonstrates the structural conformational change upon binding of GGPP. The α and β subunits 
of both proteins are displayed in cartoon and Zn2+ in sphere representation. The Binding of the GGPP to 
RabGGTase results in the rotation or displacement of side chains of the residues F293β, Y241β, W244β 
and Y195β, which are shown in stick representation. (C) Hydrogen bonding of the diphosphate moiety of 
GGPP is displayed in the stick representation. Residues of the α and β subunits are coloured in green and 
gray, respectively. Hydrogen bonds are shown as blue dashed lines. 
The diphosphate moiety of the GGPP molecule binds in a positively charged cluster at the 
subunit interface, which is formed by Arg232β, Lys235β and Lys105α, and is close to the 
catalytic zinc ion (Figure 4.13 A and B). The resolution of the structure allows 
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unambiguously determination of residues that form hydrogen bonds with the diphosphate 
moiety of the GGPP molecule. One oxygen atom of the β-phosphate forms two 2.6 Å 
hydrogen bonds with residues Lys235β and Lys105α (Figure 4.13 C), while one oxygen atom 
of the α-phosphate forms 2.7 Å and 2.5 Å hydrogen bonds with Arg232β and a water 
molecule and the other oxygen atom of the α-phosphate forms a 3.0 Å hydrogen bond with 
His190β (Figure 4.13 C). 
The most interesting aspect of the obtained structure is its comparison with the structure of 
the GTTase-I:GGPP complex89. Carbons 1-7 of GGPP adopt different conformations and are 
located much closer to the Zn2+ atom in RabGGTase than in GGTase-I (Figure 4.14).  The 
carbon atoms 8-15 superimpose very well while the last portions of the isopenoids are 
positioned differently. The binding sites can be divided into two halves based on their 
conservation. The part of the binding site harboring phosphate groups and carbons 1-12 of the 
isoprenoid chain are invariant and adopt very similar positions in both enzymes. However the 
bottom of the binding site appears to be less conserved. While some substitutions, such as 
Phe53β(GGTase-I) to Trp52β(RabGGTase), Phe52β(GGTase-I) to Tyr51β(RabGGTase), do 
not lead to significant changes in the shape of the binding site or its hydrophobicity, several 
other substitutions such as Leu320β(GGTase-I) to Phe289β(RabGGTase), Tyr323β(GGTase-
I) to Leu292β(RabGGTase), Tyr126β(GGTase-I) to Leu99β(RabGGTase) and 
Asn345β(GGTase-I) to Cys314β(RabGGTase) change both properties of the active site. 
Compared to GGTase-I the lipid binding site of RabGGTase is expanded at the bottom, 
primarily due to the substitution of Tyr323β(GGTase-I) and Tyr126β(GGTase-I) to 
Leu292β(RabGGTase) and Leu99β(RabGGTase), respectively (Figure 4.14). These 
substitutions are responsible for the bend in the last 5 carbon atoms of GGPP associated with 
RabGGTase. 
Results and discussions
 
 
 
60
 
Figure 4.14: Comparison of the RabGGTase:GGPP structure with the structure of GGTase-I:GGPP 
complex (1N4Q)89 by superposition. The active site of RabGGTase is displayed in surface representation 
while the residues of the active site of GGTase-I are displayed in stick representation. GGPP bound to 
RabGGTase is coloured in magenta and bound to GGTase-I in yellow, while the zinc ion is shown as a 
sphere. 
4.8 The structures of RabGGTase_αΔLRRΔIG in complex with 
FPP, GGMP and GGTP 
The affinities of the isoprenoids farnesyl pyrophosphate (FPP), geranylgeranyl 
monophosphate (GGMP), geranylgeranyl pyrophosphate (GGPP) and geranylgeranyl 
triphosphate towards RabGGTase had been determined by Yaowen Wu using a previously 
established assay, in which binding of isoprenoid to prenytransferase can be monitored by the 
influence of the former on the interaction of prenyltransferase with a fluorescent isoprenoid 
analogue (mant-FPP or NBD-FPP)208. Remarkably, although FPP binds to RabGGTase with 
an affiniy of ca. 90nM, i.e. >100 times weaker than the native substrate GGPP, all three 
phosphorylated forms of geranylgeraniol (GGMP, GGPP and GGTP) bind with comparably 
high affinities to RabGGTase (3 nM, 0.8 nM and 1 nM, respectively)199. 
The ability of the isoprenoids to bind tightly to RabGGTase prompted us to test whether 
phosphoisoprenoids other than the native substrate could be lipid donors in the Rab 
prenylation reaction. Two in vitro Rab prenylation assays described by Rak et al127 and in by 
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Wu et al199 were performed by Yaowen Wu 199. Briefly, these data suggest that FPP still 
served as a lipid substate and that in contrast GGMP, GGTP and FTP could not serve as lipid 
donors in the Rab prenylation reaction. 
In order to gain further insight into the mode of isoprenoid binding to RabGGTase and the 
basis for the large difference in binding strength and in transfer efficiency the complex 
structures of the truncated RabGGTase in complex with FPP, GGMP or GGTP have been 
determined and are described as follows. 
 
Figure 4.15: Crystals of RabGGTase_αΔLRRΔIG mutant in complex with FPP (left), GGMP (middle) or 
GGTP (right) obtained by a co-crystallisation approach. 
The preparation of the crystals of RabGGTase_αΔLLRΔIG in complex with FPP, GGMP or 
GGTP, as well as the collection of diffraction data, the subsequent processing and the final 
structural determination were performed as described in the structural determination of the 
truncated RabGGTase in complex with GGPP by the co-crystallisation approach. All crystals 
appeared within 1 day, with a rectangular shape and a size of approximately 40*40*100 µm 
(Figure 4.15). The shape of the complex crystals is different from the shape in the case of the 
apo enzyme, while it is similar to the enzyme:GGPP complex. All crystals belong to space 
group P212121 and contain one copy of the RabGGTase_αΔLLRΔIG complex in the 
asymmetric unit. Full data collection and refinement statistics are summarized in Table 4.2. 
Structure factors and coordinates will be deposited in the Protein Data Bank with entry codes 
xxxx (RabGGTase_αΔLRRΔIG:FPP), yyyy (RabGGTase_αΔLRRΔIG:GGMP) and zzzz 
(RabGGTase_αΔLRRΔIG:GGTP). 
The complex structures of the truncated RabGGTase in complex with FPP, GGMP and GGTP 
were determined at 1.85 Å, 2.55 Å and 2.0 Å, respectively by molecular replacement. Initial 
difference density electron maps (fofc-map) showed strong positive density in the 
hydrophobic cavity of the α-α barrel of the β subunit (Figure 4.16).  
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Figure 4.16: Difference electron density of FPP (upper, left) , GGMP (upper, right) and GGTP (bottom) 
displayed at 2.5 σ. The electron density (fofc-map) was calculated before incorporation of the 
phosphoisoprenoids into the model. The truncated RabGGTase and phosphoisoprenoid molecules are 
displayed in ribbon and stick, respectively. In the case of GGTP, one Ca2+ ion (orange) was modeled into 
the structure. 
One molecule of respective phosphoisoprenoid was modeled into the density observed and 
final rounds of refinement were performed using a restraints library generated with PRODRG. 
The quality of the final electron density map together with a comparison of the refined 
temperature factors of phosphoisoprenoids (FPP ~40 Å2; GGMP ~40 Å2 and GGTP ~20 Å2) 
and the surrounding protein residues (~25 Å2, ~30 Å2 and ~18 Å2, respectively) suggest that 
the occupancy of FPP, GGMP and GGTP in the structure is approximately 70%, 80% and 
90%, respectively. 
The final model of the RabGGTase_αΔLRRΔIG:FPP complex contains 215 water molecules, 
one FPP molecule, one Zn2+ ion and one Ca2+ ion. The structure was refined to an R-factor of 
20.4 % and Rfree of 23.5 %. The RabGGTase_αΔLRRΔIG:GGMP complex contains 36 water 
molecules, one GGMP molecule and one Zn2+ ion. The structure was refined to an R-factor of 
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21.7 % and Rfree of 29.1 %. The RabGGTase_αΔLRRΔIG:GGTP complex contains 290 water 
molecules, one GGTP molecule, one Zn2+ ion and one Ca2+ ion. The structure was refined to 
an R-factor of 19.6 % and Rfree of 23.5 %. All complexes contain one α/β heterodimer in the 
asymmetric unit. Of the total residues for the complex structures, 91.2 % (in FPP complex), 
88.5 % (in GGMP complex) and 91.3 % (in GGTP complex) lie in the most favoured region 
of the Ramachandran plot (PROCHECK). Most of the residues with poorer electron density 
are located in the additionally allowed regions. 
Comparison of the complex structures of truncated RabGGTase with its native lipid donor 
GGPP and the other phosphoisoprenoids by superposition of the β subunit demonstrated that 
in all cases the last 12 carbons of the isoprenoid moiety adopt a very similar conformation and 
position (Figure 4.17 ABC). Binding of these phosphoisoprenoids to RabGGTase leads to 
conformational changes identical to that upon binding of GGPP to the enzyme, involving 
rotation or displacement of side chains of the hydrophobic residues Phe293β, Tyr241β, 
Trp244β and Tyr195β (see Figure 4.13 B). Remarkably, the reactive carbon 1 of FPP is 
located 5 Å away from the position occupied by the C1 of native GGPP (Figure 4.17 A). 
There, the β phosphate forms a strong hydrogen bond (2.3 Å) with Tyr241β, which is 
otherwise not involved in interaction with the phosphates in the RabGGTase:GGPP structure 
(Figure 4.17 D and Figure 4.13 C). In addition, five water molecules form a network of 
hydrogen bonds to contribute to the binding of FPP to RabGGTase (Figure 4.17 D). The large 
difference in binding strength between FPP and GGPP can be explained by comparison of the 
complex structures of RabGGTase:FPP and RabGGTase:GGPP. On the one hand, the absence 
of one isoprene unit in the case of FPP would reduce the hydrophobic interaction of lipid tail 
with enzyme; on the other hand, in the complex structure with GGPP four strong hydrogen 
bonds are formed between diphosphate group and lipid binding site, whereas only one 
hydrogen bond is formed in the structure of RabGGTase complexed with FPP. This leads to 
>100 fold difference in the affinities of FPP and GGPP towards RabGGTase. The C1 atom of 
FPP is definitely too far away from the Zn2+ ion to participate in catalysis. However FPP still 
serves as an effective lipid substrate125. The most likely explanation for the observed 
reactivity of FPP is its ability to slide along the lipid binding site and coordinate with reactive 
cysteine and the catalytic Zn2+ ion.  
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Figure 4.17: Structural analysis of the truncated RabGGTase in complex with FPP, GGMP and GGTP. 
(A-C) Superimposition of the RabGGTase in complex with the native lipid donor GGPP and the other 
phosphoisoprenoids FPP (A), GGMP (B) and GGTP (C). The active site of RabGGTase in complex with 
GGPP is shown in surface representation. The GGPP is shown in stick representation and coloured in 
green. The other phosphoisoprenoid molecules are also shown in stick representation but are displayed 
colour-coded for atom types. All Zn2+ ions are displayed as yellow spheres. (D-F) Hydrogen bonding of the 
phosphate groups of the phosphoisoprenoids is shown as dashed lines. The residues of the α and β subunit 
are coloured in green and gray. The hydrogen bonds are shown as blue dashed lines. Water molecules 
(red), Zn2+ ions (yellow) and in the case of GGTP the Ca2+ ion (cyan) are shown as spheres. 
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The structure of the RabGGTase:GGMP complex is very similar to that of the complex with 
GGPP (Figure 4.17 B). Due to the absence of the β-phosphate only one 2.5 Å hydrogen bond 
is formed by the α-phosphate of GGMP and residue Arg232β (Figure 4.17 E), which is also 
involved in the binding of GGPP to RabGGTase. 
The complex containing GGTP shows significant differences (Figure 4.17 C). The last 12 
carbons of GGTP superimpose well with all other structures but the rest of the isoprenoid 
chain of GGTP adopts a conformation similar to that observed in the GGTase-I:GGPP 
complex89. This involves flipping of the first 8 carbons of GGTP away from Zn2+ on the 
carbon 9. As a result the reactive carbon 1 of GGTP is located 3 Å away from the position 
occupied by the C1 of native GGPP (Figure 4.17 C). The flipping also leads to an inward 
movement of the side chain of His190β (Figure 4.17 F). The phosphate atoms occupy similar 
positions in both structures of truncated RabGGTase bound either to GGPP or GGTP. 
However the triphosphate of GGTP forms a bend due to its interaction with a Ca2+ ion present 
in the active site. The phosphate groups of GGTP form 5 additional hydrogen bonds with the 
lipid binding site (Figure 4.17 F). Lys105α forms a 2.8 Å hydrogen bond with the α-
phosphate of GGTP, whereas it forms a hydrogen bond with the β-phosphate in the case of 
GGPP in the RabGGTase:GGPP structure. Tyr241β forms a 2.7 Å hydrogen bond with one 
oxygen atom of the β phosphate of GGTP, which is otherwise not involved in interaction with 
phosphates in the RabGGTase:GGPP structure (Figure 4.17 F and Figure 4.13 C). The other 
oxygen atom of the β phosphate of GGTP forms two 2.9 Å hydrogen bonds with His190β and 
Arg232β (Figure 4.17 F). Lys235β forms a 2.7 Å hydrogen bond with the γ-phosphate of 
GGTP (Figure 4.17 F). In addition 10 water molecules and a Ca2+ ion form a hydrogen 
bonding network that contributes to the binding of GGTP to RabGGTase. The structural data 
only provides limited clues as to why GGTP and GGMP fail to serve as lipid donors of 
RabGGTase. 
4.9 Phosphoisoprenoid specificity of protein prenytransferases 
One of the key functional differences among the three protein prenyltransferases is their 
ability to selectively utilise either GGPP or FPP. The critical feature that distinguishes GGPP 
from FPP is the length of the lipid. The availability of the structures of the three 
prenyltransferases complexed with the respective isoprenoid substrate gives mechanistic 
insights into lipid substrate specificity of protein prenyltransferases. Superimposition of these 
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three protein prenytransferases in complex with their respective phosphoisoprenoid substrate 
(PDB code 1FT2, 1N4P)89;96 provides an explanation on how the lipid’s length is used to 
selectively bind the correct substrate (Figure 4.18). 
The structures of the three protein prenytransferases in complex with their respective 
isoprenoid substrate indicate that the first three isoprene units of FPP and GGPP are in a 
linear fashion. The fourth isoprene unit of GGPP in both GGTase-I and RabGGGTase 
complexes is turned ~90° relative to this axis. This geometry of the bound lipid is quite 
different from that of the other known structures with bound isoprenoids, i.e. FTase (PDB 
code 1FT296), Rho:GDI (PDB code 1DOA209), phosducin-Gtβγ complex (PDB code 
1A0R210), Ypt1:GDI (PDB code 2BCG75) and Rab7:REP-1 (PDB code 1VG0127), in which 
the isoprenoid chains are extended. 
 
Figure 4.18: Superimposition of active sites of all three protein prenyltransferase. The three 
prenyltransferases in complex with their respective isoprenoid substrates were superimposed89;96. Only 
critical residues forming the bottom of the active sites and isoprenoids are shown in stick representation, 
while Zn2+ ions are represented as spheres. 
The alignment in Figure 4.18 shows that the second and third isoprene units are at similar 
positions in all three cases, whereas the fourth isoprene unit of the GGPP is positioned 
differently. Two striking differences in the arrangements of the bottom of the hydrophobic 
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funnel are observed, where the fourth isoprene unit of GGPP binds in GGTase-I and 
RabGGTase. Here, FTase has bulky tryptophan and tyrosine residues (Trp102β and Tyr154β). 
In contrast, the corresponding positions in GGTase-I are occupied by one smaller residue, 
threonine, and one identical tyrosine residue (Thr49β and Tyr126β), while in RabGGTase 
these positions are occupied by two smaller residues, serine and leucine (Ser48β and Leu99β). 
This suggests that residues positioned at the bottom of the hydrophobic funnel are the primary 
determinant of lipid specificity. In FTase, the tryptophan residue Trp102β and the Tyrosine 
residue Tyr154β fill the space where the fourth isoprene unit binds in GGTase-I and 
RabGGTase, respectively. 
Initial studies suggested that when GGPP was bound to the active site of FTase, its 
pyrophosphate was located too far away from the catalytic Zn2+ ion for reaction to occur89;96. 
However, comparison of the structures of FTase in complex with FPP (PDB code 1FT2) and 
GGPP (PDB code 1O1R)211 indicates that the diphosphate group and the last two isoprene 
units of GGPP and FPP adopt a very similar conformation and position. As a result, the first 
and second isoprene units of GGPP bulge away from the CAAX substrate binding site. As 
mentioned above the FPP rotates at its third isoprene unit and brings the C1 atom of FPP 
closer to the activated cysteine thiolate to allow the farnesylation to take place. However, 
superimposition of the FTase in complex with FPP, GGPP and farnesylated CAAX peptide 
reveals that the bulkier isoprenoid GGPP cannot undergo this conformational change without 
unfavorable steric interactions with the CAAX substrate211. This explains why GGPP and FPP 
bind to FTase with comparable affinities but only FPP serves as an effective 
substrate16;92;99;103;106. 
The residues Phe324β of GGTase-I and Phe293β of RabGGTase are also positioned near the 
fourth isoprene unit; the hydroxyl group on the corresponding FTase Tyr365β residue may 
also help to discriminate against GGPP binding in FTase. These data demonstrate that in the 
case of FTase steric hindrance plays the central role in choosing the correct lipid substrate. 
Unlike FTase, GGTase-I and RabGGTase can (mis)transfer a farnesyl group to substrate 
proteins. Although in the RabGGTase:FPP structure the C1 of FPP is too far away from the 
zinc ion to participate in the reaction with the Zn2+ activated cysteine thiolate, RabGGTase 
transfers GGPP and FPP at a similar rate125. This suggests that FPP can slide in the active site 
to allow this reaction to take place. This must occur relatively easily to account for the 
prenylation reaction, and the rate of sliding must be rapid compared with the actual lipid 
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transfer reaction. Though in vitro FPP serves as an effective lipid substrate for RabGGTase, in 
vivo Rab proteins appear to only undergo geranylgeranylation mediated by RabGGTase107;199. 
This is first explained by weaker affinities of FPP for the enzymes (330-fold to GGTase-I and 
100-fold to RabGGTase)101;106;199. In addition, reaction cycle progression requires the binding 
of fresh isoprenoid diphosphate to displace the product from the active site88;89. Due to the 
much lower affinity of FPP towards GGTase, as compared with GGPP, the displacement is 
more difficult with FPP than with GGPP, which results in a reduced tendency for FPP to bind 
to GGTase during the reaction cycle. This leads to selection of GGPP in preference to FPP as 
lipid donor in GGTase-I and RabGGTase. 
These conclusions were confirmed by mutagenesis studies. A mutation at the Trp102β residue 
of FTase to a threonine (the corresponding residue in GGTase-I) or a mutation at the Tyr154β 
residue of FTase to a threonine/leucine (the corresponding residue in RabGGTase) were 
tested and both single mutations result in an FTase enzyme greatly preferring GGPP over FPP 
as its isoprenoid substrate without significantly altering the CAAX sequence specificity105;212. 
The reason for the different binding of the fourth isoprene unit of GGPP in GGTase-I and 
RabGGTase can be explained by the presence of the bulky tyrosine residue (Tyr126β) in 
GGTase-I, whereas the corresponding position in RabGGTase is replaced by a smaller 
residue, leucine (Figure 4.18). 
4.10 Design of FTase and GGTase-I mutants capable of utilising 
Biotin-GPP as a lipid substrate 
Expansion of the bottom of the lipid binding site in RabGGTase relative to those of FTase and 
GGTase-I enables it to bind phosphoisoprenoid analogues with bulky terminal groups. This 
idea finds support in a recent report demonstrating that of the three protein prenyltransferases, 
only RabGGTase can use the bulky biotingeranyl pyrophosphate (Biotin-GPP) as substrate202 
(Figure 4.20). Incorporation of the biotin group by RabGGTase into its cognate substrates 
enables rapid monitoring of the prenylation status of RabGTPases across the proteome. It 
enables an analysis of numerous aspects of RabGTPase biogenesis such as expression profiles 
in different cell types, the rates of Rab expression and prenylation, and the effect of 
prenylation inhibitors on Rab prenylation. Expansion of this technology to other 
prenyltransferases would be of great value. 
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Based on the obtained structural information on the RabGGTase:isoprenoid complexes, we 
engineered two FTase and GGTase-I mutants: FTase(W102T, Y154T) and GGTase-
I(Y126T). In these mutants the bottom of the hydrophobic funnel was enlarged to resemble 
that of RabGGTase (Figure 4.19). 
 
Figure 4.19: Design of FTase and GGTase-I mutants capable of using Biotin-GPP as substrate. The three 
prenyltransferases in complex with their respective isoprenoid substrates were superimposed and 
displayed as blue (FTase), orange (GGTase-I) and green (RabGGTase) cartoons. The critical residues that 
were selected for mutation studies and isoprenoids are shown as sticks, while Zn2+ ions are displayed as 
spheres. 
Unlike the parental enzymes the obtained mutants were capable of specifically conjugating 
Biotin-GPP to their cognate protein substrates. However, the transfer efficiency of GGTase-
I(Y126T) is much lower than that of FTase(W102T,Y154T) and RabGGTase (Figure 4.20). 
 
Figure 4.20: Incorporation of Biotin-geranyl into GTPases mediated by prenyltransferases in vitro 
adopted from212. KiRas, RhoA, and Rab7 were prenylated by FTase, GGTase-I or RabGGTase, 
respectively, using Biotin-GPP as a lipid donor. The reaction products were detected by Western blotting 
with STR-HRP. (This experiment was performed by U.T. Nguyen.) 
Results and discussions
 
 
 
70
We conjectured that the missing polar interaction of the Biotin group with the active site of 
GGTase-I(Y126T) may have resulted in the lower efficiency Biotin-transfer. A comparison of 
residues defining the active site of the three enzymes demonstrated a difference in the 
positioning of Phe53β of GGTase-I by Trp106β of FTase and Trp52β of RabGGTase at the 
corresponding position (Figure 4.19). A polar interaction might be formed by the Biotin group 
with the indole group of tryptophan. Based on this analysis a new GGTase-I(Y126T, F53Y) 
mutant was generated, in which Tyr126β and Phe53β were mutated to threonine and tyrosine, 
respectively. Indeed, the new GGTase-I mutant was shown to engage Biotin-GPP as substrate 
with an efficiency comparable to that of RabGGTase and FTase(W102T, Y154T)212 (Figure 
4.20). These mutants and RabGGTase can be used to rapidly identity, isolate and characterize 
all prenylatable proteins in mammalian cell providing a new technological venue in protein 
prenyltransferase research. 
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Section IV 
Structural studies of the Rab prenylation process 
4.11 Structures of the truncated RabGGTase in complex with 
mono- and di-prenylated Rab7 C-terminal peptides 
The ability to perform two sequential geranylgeranyl transfer reactions on a single peptide 
substrate is a salient feature of RabGGTase. One of the longstanding questions in the field 
was the location of the first conjugated isoprenoid during the second transfer reaction. 
Comparison of the structures of GGTase-I and RabGGTase led to speculations that the first 
conjugated isoprenoid would be located in the cavity near the reaction center89. The success in 
generating the RabGGTase:substrate complexes promoted us to attempt crystallisation of 
enzyme bound to the reaction intermediate and product. Three prenylated peptides, Ser-Cys-
Ser-Cys(GG), Ser-Cys(GG)-Ser-Cys and Ser-Cys(GG)-Ser-Cys(GG), were generated by Dr. 
D. Das (Department 4, MPI Dortmund) using solid phase synthesis to mimic the mono- and 
di-prenylated C-terminus of Rab7. These peptides represent all three possible prenylation 
states of Rab7 and also give a good coverage of possible positions of geranylgeranyl group in 
the C-terminus of Rab7. 
Determination of the affinities of the prenylated peptides towards RabGGTase was 
unsuccessful by ITC measurement, perhaps due to the low aqueous solubility of these 
peptides. Following the observation that these prenylated peptides bind to RabGGTase in a 
mode similar to that of native phosphoisoprenoids (described below), a competitive titration 
was performed to determinate the affinities of these prenylated peptides towards RabGGTase. 
The binding of isoprenoid with prenytransferase was monitored by the influence of the former 
on the interaction of the prenyltransferase with the fluorescent isoprenoid analogue (NBD-
FPP)125;208. 
The competitive titration was carried out as described in Materials and Methods (3.4.2). 200 
nM NBD-FPP was mixed with 1 µM prenylated peptide in 50 mM Hepes pH 7.2, 50 mM 
NaCl, 2 mM MgCl2, 5 mM DTE and 2% DMSO. The mixture was titrated with increasing 
concentrations of RabGGTase. NBD-FPP was excited at 487 nm and the fluorescence was 
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monitored at 550 nm. The decrease in fluorescence upon addition of the protein was 
measured, and at each step the values were averaged after equilibration. 
 
Figure 4.21: Determination of affinities of prenylated peptides towards RabGGTase by a competitive 
titration approach using the fluorescent isoprenoid analogue NBD-FPP. (A) Raw data of competitive 
titrations. The titration was carried out as described in Materials and Methods (3.4.2). NBD-FPP was 
excited at 487 nm and the fluorescence was monitored at 550 nm. Relative fluorescence was plotted 
against time. (B) Fit of the data. The relative fluorescence was plotted against concentration of 
RabGGTase. The curve for titration of 200 nM NBD-FPP alone was fitted resulting in a Kd of 0.4 µM, 
which was consistent with previous studies208. This Kd value was used to fit the data of the competitive 
titrations. 
To determinate the Kd value for NBD-FPP, 200 nM NBD-FPP alone was titrated with 
increasing concentrations of RabGGTase. The Kd-values were obtained by drawing a fit to the 
data using program Scientist 2.0 as described125 (Table 4.1). 
Table 4.1: Affinities of NBD-FPP and prenylated peptides towards RabGGTase. 
 NBD-FPP Ser-Cys-Ser-Cys(GG) Ser-Cys(GG)-Ser-Cys Ser-Cys(GG)-Ser-Cys(GG) 
Kd (µM) 0.4 1.3 1.0 1.8 
These data demonstrate that both mono-prenylated and di-prenylated peptides bind with 
comparable affinities to RabGGTase, however >1000 times more weakly than the isoprenoid 
substrate GGPP and ~2-5 times more weakly than NBD-FPP. 
Preparation of crystals of the truncated RabGGTase complexed with the prenylated peptides, 
as well as the collection of diffraction data, the subsequent processing and the final structural 
determination were performed as described in the structural determination of the truncated 
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RabGGTase in complex with phosphoisoprenoids by the co-crystallisation approach (4.7). To 
improve the occupancy of these prenylated peptides in crystals 2.5 % DMSO was used in the 
reservoir solution and cyrosolution. 
All crystals appeared within 2 days with a rectangular shape and a size of approximately 
30*30*70 µm (Figure 4.22). The shape of the obtained crystals was different from the shape 
in the case of the apo enzyme, whereas it is similar to that of the enzyme:GGPP complex. All 
crystals belong to space group P212121 and contain one copy of the RabGGTase_αΔLLRΔIG 
complex in the asymmetric unit. Full data collection and refinement statistics are summarized 
in Table 4.2. Structure factors and coordinates will be deposited in the Protein Data Bank with 
entry codes xxxx (RabGGTase αΔLRRΔIG:Ser-Cys-Ser-Cys(GG)), yyyy (RabGGTase 
αΔLRRΔIG: Ser-Cys(GG)-Ser-Cys), and zzzz (RabGGTase αΔLRRΔIG: Ser-Cys(GG)-Ser-
Cys(GG)). 
  
Figure 4.22: Crystals of RabGGTase_αΔLRRΔIG mutant in complex with Ser-Cys-Ser-Cys(GG) (left), 
Ser-Cys(GG)-Ser-Cys (middle) or Ser-Cys(GG)-Ser-Cys(GG) (right) obtained by co-crystallisation 
approach. 
The structures of the truncated RabGGTase in complex with Ser-Cys-Ser-Cys(GG), Ser-
Cys(GG)-Ser-Cys and Ser-Cys(GG)-Ser-Cys(GG) were determined at 1.9 Å, 2.1 Å and 2.0 Å 
resolution, respectively by molecular replacement. Initial difference electron density maps 
(fofc-map) showed strong positive density in the hydrophobic cavity of the α-α barrel of the β 
subunit (Figure 4.23). 
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Figure 4.23: Difference electron density of Ser-Cys-Ser-Cys(GG) (upper, left), Ser-Cys(GG)-Ser-Cys 
(upper, right), Ser-Cys(GG)-Ser-Cys(GG) (bottom) displayed at 2.5 σ. The electron density (fofc-map) was 
calculated before incorporation of the prenylated peptides into the model. The truncated RabGGTase and 
prenylated peptides are displayed in ribbon and stick representation, respectively. 
One molecule of the respective prenylated peptide was modeled into the density observed and 
final rounds of refinement were performed using a restraints library generated with PRODRG. 
The quality of the final electron density map together with a comparison of the refined 
temperature factors of the prenylated peptides (Ser-Cys-Ser-Cys(GG) ~16 Å2; Ser-Cys(GG)-
Ser-Cys ~25 Å2 and Ser-Cys(GG)-Ser-Cys(GG) ~20 Å2) and the surrounding protein residues 
(~32 Å2, ~50 Å2 and ~40 Å2, respectively) suggests that the occupancy of these three 
prenylated peptides in the structure is approximately 50 %. 
The final model of RabGGTase_αΔLRRΔIG:Ser-Cys-Ser-Cys(GG) complex contains 386 
water molecules, one Ser-Cys-Ser-Cys(GG) molecule, one Zn2+ ion and one Ca2+ ion. The 
structure is refined to an R-factor of 16.1 % and Rfree of 22.1 %. The 
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RabGGTase_αΔLRRΔIG:Ser-Cys(GG)-Ser-Cys complex contains 153 water molecules, one 
Ser-Cys(GG)-Ser-Cys molecule, one Zn2+ ion and one Ca2+ ion. The structure is refined to an 
R-factor of 17.2 % and Rfree of 23.3 %. The RabGGTase_αΔLRRΔIG:Ser-Cys(GG)-Ser-
Cys(GG) complex contains 203 water molecules, one Ser-Cys(GG)-Ser-Cys(GG) molecule, 
one Zn2+ ion and one Ca2+ ion. The structure is refined to an R-factor of 18.1 % and Rfree of 
24.1 %. All complexes contain one α/β heterodimer in the asymmetric unit. Of the total 
residues for the complex structures, 91.9 % (in Ser-Cys-Ser-Cys(GG) complex), 92.7 % (in 
Ser-Cys(GG)-Ser-Cys complex) and 92.3 % (in Ser-Cys(GG)-Ser-Cys(GG) complex) lie in 
the most favoured region of the Ramachandran plot (PROCHECK). Most of the residues with 
poorer electron density are located in the additionally allowed regions. 
In all three cases the lipid binding site was occupied by a single geranylgeranyl moiety 
(Figure 4.24). Binding of the geranylgeranyl moiety of the prenylated peptides to RabGGTase 
leads to conformational changes identical to those seen upon binding of GGPP to the enzyme, 
involving rotation or displacement of side chains of the hydrophobic residues Phe293β, 
Tyr241β, Trp244β and Tyr195β (see Figure 4.13 B). 
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Figure 4.24: Structure analysis of the truncated RabGGTase in complex with Ser-Cys-Ser-Cys(GG), Ser-
Cys(GG)-Ser-Cys and Ser-Cys(GG)-Ser-Cys(GG). (A-C) Superimposition of the RabGGTase in complex 
with native lipid donor GGPP and the prenylated peptides Ser-Cys-Ser-Cys(GG) (A), Ser-Cys(GG)-Ser-
Cys (B) and Ser-Cys(GG)-Ser-Cys(GG) (C). The active site of RabGGTase in complex with prenylated 
peptides is shown in surface representation. The geranylgeranyl moiety of prenylated peptides and GGPP 
molecules are shown in stick representation and coloured in magenta and green, respectively. Zn2+ is 
displayed as a yellow sphere. 
In the case of RabGGTase in complex with Ser-Cys(GG)-Ser-Cys the isoprenoid chain was 
traceable only to the last 12 carbon atoms and in the case of RabGGTase complexed with Ser-
Cys-Ser-Cys(GG) to the last 15 (Figure 4.24). For the diprenylated peptide Ser-Cys(GG)-Ser-
Cys(GG) bound to RabGGTase the entire isoprenoid chain was visible. Comparison of the 
RabGGTase:GGPP complex structure with that bound to the prenylated peptides 
demonstrated that in all cases the traceable carbon atoms of the prenylated peptides and the 
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respective carbon atoms of the GGPP adopt very similar conformations and positions (Figure 
4.24). This suggests that RabGGTase has only one specific geranylgeranyl moiety binding 
site available for the association of substrates, reaction intermediates and product. 
The invisibility of the peptide chain in the presented structures is not completely surprising. 
The selection of protein substrates in RabGGTase differs from the CAAX prenyltransferases. 
The CAAX prenyltransferases recognize the CAAX-motif of their protein substrates. 
However, RabGGTase must accommodate variations in the C-termini of Rab proteins. 
Previous studies126 suggest that there appears to be no strict order of first isoprenoid addition. 
Thus, unlike the CAAX prenyltransferases, RabGGTase does not anchor the C-terminus of 
Rab substrates, explaining the lack of electron density in the determined structures. 
The structures of FTase and GGTase-I in complex with both isoprenoid substrate and 
prenylated peptide product (PDB codes 1KZO and 1N4S, respectively) reveal that binding of 
the fresh isoprenoid diphosphate substrate dislodges the prenyl group of the prenylated 
peptides to an ‘exit groove’ (Figure 1.7), which is formed by helices 1 and 2 and the tip of the 
helix 12 and which is conserved in the protein prenyltransferase family88-90. The original 
studies of GGTase-I and FTase led to the proposal that during Rab geranylgeranylation, the 
first conjugated lipid chain translocates to the conserved ‘exit groove’ in RabGGTase by 
displacement of fresh isoprenoid substrate. Additionally, a tunnel located next to the lipid 
binding site of RabGGTase may serve to stabilize the mono-prenylated product during the 
processive reaction88;89. Based on the structures presented here, these two scenarios appear to 
be unlikely since no additional electron density could be detected in this region in any of the 
solved structures. 
The invisibility of the second lipid chain and peptide chains in the structures of RabGGTase 
in complex with prenylated peptide suggests that there is no specific binding site for 
association of the dislodged mono-prenylated C-terminus of Rab. It does not form stabilizing 
interactions with the active site of RabGGTase. This is consistent with the determined 
affinities of the prenylated peptides towards RabGGTase. The second lipid chain does not 
positively contribute to the affinity of interaction. The second isoprenoid conjugation is 
carried out when the thiol of the second C-terminal cysteine is activated by zinc ion. The first 
conjugated lipid probably provides sterical hindrance for the second cysteine. As a result, the 
rate of the second transfer step (0.039 s-1) is 4 times slower than the first one (0.16 s-1), 
despite the higher affinity of the ternary complex120;121;126. 
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4.12 Model of Rab prenylation process 
Based on the presented structures and on available biochemical results on Rab prenylation a 
reaction model is proposed for RabGGTase (Figure 4.26)120-126. 
The Rab prenylation mechanism is different from that of the CAAX protein 
prenyltransferases. An additional protein factor, REP, is needed for Rab prenylation and 
usually Rab proteins undergo double geranylgeranylation118. A Rab protein, REP and 
RabGGTase associate together as a ternary protein complex during the Rab 
geranylgeranylaion. Based on available biochemical data two possible mechanisms were 
proposed for the formation of the ternary protein complex (Figure 4.26)120-126. In ‘classical’ 
mechanism of Rab prenylation, the unprenylated Rab interacts with REP first, followed by 
association of this complex with RabGGTase. The affinity of REP for RabGGTase is 
increased by the binding of either Rab or GGPP. This observation has led to proposition of an 
‘alternative’ mechanism for the formation of the ternary protein complex123, that REP 
associates with RabGGTase bound to GGPP to form a binary protein complex followed by 
binding to Rab protein. However,the physiological significance of the presence of these two 
mechanism is still unclear92. 
REP-1 forms a complex with RabGGTase via the interactions between the α-subunit of 
RabGGTase and domain II of the REP93. The assembly of the binary Rab:REP complex is 
triggered by the recognition of the GTPase domain of Rab by the Rab binding platform (RBP) 
of REP127. In addition, interactions of the C-terminal interaction motif (CIM), formed by two 
discontinuous leucine, valine or isoleucine residues near the C-terminus of Rabs, with the C-
terminal binding region (CBR) of REP-1 play an important role for the association of the C-
terminus of Rabs to the active site of RabGGTase119. Single mutations in the CIM motif (e.g. 
Rab7I190H and Rab7L192S) result in a 30-70 fold reduction in Rab7:REP-1 affinity and the 
double mutant Rab7(I190H,L192S) showed no detectable prenylation199. This suggests that 
CIM could be viewed as being functionally analogues to the AAX motif of the CAAX box in 
the case of FTase and GGTase-I, but working from a remote location. In other words both the 
enzyme and the substrate have “outsourced” their specificity, to the accessory factor (REP) 
and to a remote upstream sequence respectively. The consequence of such arrangement allows 
the active site to accommodate a broad variety of C-terminal sequences. However it reduces 
Results and discussions
 
 
 
79
the rate of the prenylation reaction. Compared to FTase, the rate (0.16 s-1) of the first 
geranylgeranylation of Rab7 mediated by RabGGTase is over 100-fold slower88;126. 
As there is no detectable binding of the Rab C-terminus to RabGGTase, the ternary complex 
of RabGGTase in complex with a nonreactive isoprenoid analogue and the C-terminus of 
Rabs could not be characterized. Superposition of truncated RabGGTase:GGPP with 
GGTase-I:peptide:GGPP analogue (PDB code 1TNB)103 could give some insight into Rab 
prenylation progression (Figure 4.25). This suggests that during the first Rab 
geranylgeranylation mediated by RabGGTase one of C-terminal cysteines of Rab is 
coordinated to the catalytic Zn2+ ion. The Zn2+ activated C-terminal thiolate reacts with C1 of 
GGPP to form a thioether linkage. 
 
Figure 4.25: Comparison of the binding of substrates in RabGGTase and GGTase-I. The truncated 
RabGGTase complexed with GGPP and GGTase-I complexed with a nonreactive GGPP analog and a 
peptide substrate KKSKTKCVIF derived from TC21 (PDB code 1TNB)103 were superimposed. The active 
site of RabGGTase is displayed in surface representation with the Zn2+ ion shown as yellow ball. GGPP 
(green), its analog (blue) and peptide (magneta) are displayed in stick representation. 
Following the first geranylgeranylation, a new GGPP molecule binds to the active site and 
dislodges the first conjugated geranylgeranyl moiety from the hydrophobic cavity. The mono-
prenylated C-terminus of Rab does not form specific interactions with the active site and 
adopts a flexible conformation. While the thiol of the second C-terminal cysteine is activated 
by Zn2+ ion, the second geranylgeranylation is carried out (Figure 4.26). Following the second 
prenylation the doubly prenlyated peptide is released by competition with another GGPP 
molecule for the lipid binding site of RabGGTase124. Subsequently the lipid chains of the 
prenylated product migrate on the surface of RabGGTase and invade the binding site on 
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domain II of the REP-1 molecule, resulting in dilation of the lipid-harboring hydrophobic 
cavity and in displacement of Phe279REP-1 and Arg290REP-1 from their binding sites on the 
α subunit of RabGGTase. These conformational changes lead to a decrease in the affinity of 
RabGGTase for the Rab:REP complex and leads to product release by the enzyme127 
(1.6.2)(Figure 4.26). 
 
Figure 4.26: Mechanistic model of RabGGTase mediated Rab prenylation. Kinetic constants were 
adopted from available biochemical data120-126. 
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Section V 
Structural studies of the engineered RabGGTase 
in complex with inhibitors 
Although numerous effective and specific inhibitors of FTase and GGTase-I (1.7) have been 
developed, so far, only one specific but weak phosphonocarboxylate inhibitor of RabGGTase 
has been reported171 in spite of the biological importance of RabGGTase and its involvement 
in the establishment of several diseases. More recent studies indicate that the inhibition of 
RabGGTase induces p53-independent apoptosis validating this enzyme as a promising target 
for anti-cancer therapy93;131. A crystal structure of RabGGTase in complex with such 
inhibitors could reveal a molecular basis for their inhibitory activities, thus facilitating the 
development of more effective and selective inhibitors by structure-guided ligand design. The 
developed inhibitors could serve as candidates for anti-cancer therapy and facilitate the 
studies of the role of RabGGTase in skeletal disorders, cancer and the biological function of 
RabGTPases. 
4.13 Structures of RabGGTase_αΔLRRΔIG in complex with 
peptidomimetic inhibitors: MT650 and MT670  
Compounds MT650 and MT670 were synthesized by Dr. M. Thutewohl213;214. Both 
compounds are potent inhibitors of FTase and RabGGTase. The IC50 and Kd values of MT670 
towards RabGGTase are 5 µM and 1.8 µM, respectively208;215. According to the kinetic results 
MT670 most probably associates with the peptide binding site of RabGGTase but might have 
a weak influence on the lipid binding site. Interaction of compound MT650 with RabGGTase 
showed a binding mode similar to compound MT670 albeit with somewhat lower affinity208. 
The chemical structures of MT650 and MT670 are shown in Figure 4.27. 
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Figure 4.27: Chemical structures of MT650 and MT670. 
The preparation of RabGGTase_αΔLLRΔIG in complex with MT650 or MT670 as well as 
the collection of diffraction data, the subsequent processing and the final structural 
determination were performed as described in the structural studies of the truncated 
RabGGTase in complex with prenylated peptides by co-crystallisation. Crystals appeared 
after 2 days with a rectangular shape and a size of approximately 40*40*100 µm (Figure 
4.28). Both crystals belong to space group P212121 and contain one copy of the 
RabGGTase_αΔLLRΔIG complex in the asymmetric unit. 
  
Figure 4.28: Crystals of the RabGGTase_αΔLRRΔIG mutant in complex with MT650 (left) or MT670 
(right) obtained by co-crystallisation approach. 
Full data collection and refinement statistics are summarized in Table 4.2. Structure factors 
and coordinates will be deposited in the Protein Data Bank206 with entry codes 3C72 
(RabGGTase_αΔLRRΔIG:MT650), and zzzz (RabGGTase_αΔLRRΔIG: MT670) 215. 
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Figure 4.29: Difference electron density of compounds MT650 and MT670, displayed at 2 σ. The electron 
density was calculated prior to incorporation of the ligands into the models. 
The structures of the RabGGTase_αΔLRRΔIG in complex with MT650 or MT670 were 
determined to 2.3 Å and 2.2 Å resolution, respectively. Initial difference electron density 
maps (fofc-map) showed strong positive density in the hydrophobic cavity of the β subunit in 
both complex structures (Figure 4.29). One molecule of MT650 or MT670, respectively, was 
fitted into the density observed, and final rounds of refinement were performed using a 
restraints library generated with PRODRG (Figure 4.29). 
The quality of the final electron density map together with a comparison of the refined 
temperature factors of MT650 or MT670 (~35 and ~30 Å2, respectively) and the surrounding 
protein residues (~70 and ~60 Å2, respectively) suggest that the occupancy of MT650 or 
MT670 is approximately 50%. 
The final model of RabGGTase_αΔLRRΔIG:MT650 complex contains 191 water molecules, 
one MT650 molecule, one Zn2+ ion and two Ca2+ ions. The structure was refined to an R-
factor of 18.9 % and Rfree of 25.6 %. The model of RabGGTase_αΔLRRΔIG:MT670 complex 
contains 95 water molecules, one MT670 molecule and one Zn2+ ion. The structure was 
refined to an R-factor of 21.0 % and Rfree of 28.3 %. Both structures contain one α/β 
heterodimer in the asymmetric unit. Of the total residues for the complex structure 
RabGGTase:MT650 and RabGGTase:MT670, 90.6 % and 89.4% lie in the most favoured 
region of the Ramachandran plot (PROCHECK), respectively. Most of the residues with 
poorer electron density are located in the additionally allowed regions, with no residue in the 
disallowed region. 
The structures demonstrate that both MT650 and MT670 bind in a similar manner to 
RabGGTase. Compounds MT650 and MT670 bind in the hydrophobic funnel which contains 
Results and discussions
 
 
 
84
the active center in the interface of the α and β subunits of RabGGTase adopting an extended 
conformation with its C-terminus pointing outward (Figure 4.30 A and B). The binding of 
these inhibitors does not induce a change in the structure of the active site. 
The interaction between RabGGTase and both inhibitors is mainly hydrophobic. In the 
structure of truncated RabGGTase complexed with MT650 only the carbamate group of the 
inhibitor forms a strong hydrogen bond (3.0 Å) to the protein, namely with the side chain of 
Arg144 of the β subunit. The imidazole moiety of MT650 appears to be part of a hydrogen 
bonding network involving several water molecules and possibly also Tyr97 (3.0 Å) of the β 
subunit (Figure 4.30 C). A weak hydrogen bond (3.4 Å) to Tyr241β anchors the C-terminal 
carboxylate group of the inhibitor. In the structure of truncated RabGGTase in complex with 
MT670 the hydrogen bond (3.2 Å) between the carbamate group of the inhibitor and the side 
chain of Arg144 of the β-subunit is also formed. Additionally, the N-terminal tyrosyl side 
chain of MT670 forms another strong hydrogen bond (2.6 Å) with the side chain of Ser48β 
and possibly also a weak hydrogen bond (3.5 Å) with the backbone of Leu96β (Figure 4.30 
D). 
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Figure 4.30: Structural analysis of truncated RabGGTase in complex with MT650 and MT670. (A-B) 
Superimposition of the structure of RabGGTase in complex with compound MT650 (A) or MT670 (B), the 
RabGGTase:GGPP structure and GGTase-I in complex with the substrate peptide KCVIF and a non-
hydrolysable analogue of GGPP (PDB code 1TNB). The active site of RabGGTase in complex with 
inhibitors is shown in surface representation. The GGPP bound to RabGGTase and the substrate peptide 
KCVIF in GGTase-I complex are shown in line representation and coloured in green and cyan, 
respectively. Zn2+ ion is represented as yellow spheres, while inhibitors are displayed in stick and in 
atomic colours. (C-D) Interaction of compound MT650 and MT670 with the active site of RabGGTase. 
The α and β subunit of RabGGTase are displayed as green and gray cartoons, respectively. The inhibitors 
and interacting side chains of the β subunit are displayed as sticks coloured by atom type. Blue dashed 
lines indicate hydrogen bonds. The Zn2+ ion and waters participatting in the interactions are shown as 
yellow and red spheres, respectively. 
Superimposition of the enzyme:inhibitor structures, the RabGGTase:GGPP structure and the 
related GGTase-I in complex with a peptide substrate and an analogue of geranylgeranyl 
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pyrophosphate (PDB code 1TNB)103 reveals that the backbone of both inhibitors as well as 
the histidyl and tyrosyl side chains of MT650 and both tyrosyl side chains of MT670 occupy 
the presumed protein substrate binding site (Figure 4.30 A and B). The side chain of the C-
terminal tyrosine is highly flexible in both structures, indicating that it may act as a general 
gatekeeper to block accessibility of the protein substrate and that its exact nature may not be 
important. The phenylalanine of compound MT650 and MT670 protrudes into the 
hydrophobic isoprenoid binding pocket and therefore provides an additional potential 
anchoring site for the inhibitor (Figure 4.30 A and B). 
Analysis of the complex structure shows more potential attachment points in the immediate 
vicinity of the bound inhibitor that could be employed to improve the affinity and specificity 
of the inhibitors. One site is formed by the Zn2+ ion and its coordinating His290β, while the 
other site (Arg232β and Lys235β) is the positively charged cluster which anchors the 
phosphate moiety of GGPP. 
The structure of truncated RabGGTase complexed with compounds MT650 or MT670 reveals 
the molecular basis for their inhibitory activities. Both inhibitors associate with the peptide 
binding site of RabGGTase but the phenylalanine side chain of these inhibitors has an 
influence on the lipid binding site. These observations are consistent with the kinetic 
results208. 
4.14 Structures of RabGGTase_αΔLRRΔIG in complex with the 
first selective peptidomimetic inhibitor: KT90102  
Compound KT90102 was more recently synthesized by Dr. K.T. Tan and demonstrated to be 
a competitive inhibitor of the isoprenoid substrate of RabGGTase215. The compound 
KT90102 shows moderate to fairly good selectivity for RabGGTase compared to FTase and 
GGTase-I and can be regarded as the first known selective low micromolar RabGGTase 
inhibitor. The IC50 towards RabGGTase is 10 µM, towards FTase and GGTase-I 35 and 60 
µM, respectively. The Kd value of this compound for RabGGTase is 1 µM215. The chemical 
structure of KT90102 is shown in Figure 4.31. 
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Figure 4.31: Chemical structure of KT90102. 
Truncated RabGGTase in complex with KT90102 was prepared by a soaking approach (3.5.3) 
as follows. 2 µl of 5 mM KT90102 in methanol were applied to a glass cover slip. After 
evaporation of the organic solvent, 2 µl of soaking solution containing 20% (w/v) PEG3350, 
0.2 M CaAc2, 0.1 M HEPES pH 7.2, 5mM DTE, 2.5 % DMSO were added. Then the crystals 
of the apo truncated RabGGTase, which were generated as described above (4.3), were 
transferred into the soaking solution. The drop was equilibrated at 12°C against 500 µl 
soaking solution for 4 days. The soaked crystals were directly flash-frozen in liquid nitrogen. 
Collection of diffraction data, the subsequent processing and the final structural determination 
were performed as described in the structural studies of the truncated RabGGTase in complex 
with phosphoisoprenoids. The crystals did not change their space group after soaking. 
Full data collection and refinement statistics are summarized in Table 4.2. The structure of the 
enzyme as a complex with KT90102 was determined to 1.95 Å resolution. Initial difference 
density electron maps (fofc-map) showed strong positive density in the hydrophobic cavity of 
the α-α barrel of the β subunit of the structure (Figure 4.32). 
 
Figure 4.32: Difference electron density of compound KT90102, displayed at 2 σ. The electron density was 
calculated prior to incorporation of the ligand into the model. 
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One molecule of KT90102 was fitted into the density observed and final rounds of refinement 
were performed using a restraints library generated with PRODRG (Figure 4.33). The quality 
of the final electron density map together with a comparison of the refined temperature factors 
of KT90102 (~80 Å2) and the surrounding protein residues (~30 Å2) suggest that the 
occupancy of KT90102 is approximately 40%. 
The final model of the RabGGTase_αΔLRRΔIG:KT90102 complex contains 183 water 
molecules, one KT90102 molecule, one Zn2+ ion and two Ca2+ ions. The structure was refined 
to an R-factor of 20.0 % and Rfree of 24.0 %. The model of the complex contains one α/β 
heterodimer in the asymmetric unit. 91.3 % of the total residues for the complex structure lie 
in the most favoured region of the Ramachandran plot (PROCHECK). Most of the residues 
with poorer electron density are located in the additionally allowed regions, with no residue in 
the disallowed region. 
The structure complex demonstrates that compound KT90102 binds in the central 
hydrophobic cavity in the interface of the α and β subunits of RabGGTase, adopting a bent 
conformation. However, the orientation of the fragment from pyridine to tyrosine of KT90102 
could not be exactly determined. This fragment seems to adopt multiple conformations in the 
complex structure, indicating that it may form unspecific interactions with the hydrophobic 
tunnel and that its exact nature may not be important. The adopting of multiple conformations 
might be explained by no pronounced sequence specificity for the C-termini of protein 
substrates of RabGGTase, in general which perhaps leads to no specific anchoring of this 
fragment of peptidomimetic in the hydrophobic tunnel of RabGGTase. 
The interaction between RabGGTase and compound KT90102 is also mainly hydrophobic. 
Superimposition of the RabGGTase:KT90102 structure, the RabGGTase:GGPP complex 
structure and the related GGTase-I in complex with a peptide substrate and an analogue of 
geranylgeranyl pyrophosphate (PDB code 1TNB)103 reveals that the decane moiety of 
KT90102 occupies the lipid substrate binding site and that the backbone of the peptide as well 
as the pyridine of KT90102 occupy the presumed protein substrate binding site (Figure 4.33). 
Remarkably, the imidazole moiety of the histidine between the other histidine and tyrosine 
tightly coordinates the catalytic Zn2+ ion blocking the activation of the thiol of the C-terminal 
cysteine of protein substrate. 
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Figure 4.33: Structural analysis of truncated RabGGTase in complex with KT90102. Superimposition of 
the RabGGTase:KT90102 structure, the RabGGTase:GGPP structure and GGTase-I in complex with 
substrate peptide KCVIF and a non-hydrolysable analogue of GGPP (PDB code 1TNB). The active site of 
RabGGTase in complex with inhibitor is shown in surface representation. The GGPP bound to 
RabGGTase and the substrate peptide KCVIF in the GGTase-I complex are shown in line representation 
and coloured in green and cyan, respectively. Zn2+ ion is represented in yellow sphere, while the inhibitor 
is displayed in stick and in atomic colours. 
The structure of truncated RabGGTase complexed with compound KT90102 reveals the 
molecular basis for its inhibitory activity. This observation is consistent with the kinetic 
results, which showed that the inhibitor associates with the lipid binding site of RabGGTase. 
Judging from this structure the inhibitor has a strong influence on the peptide binding site. 
4.15 Structure of RabGGTase_αΔLRRΔIG in complex with a 
specific inhibitor: psoromic acid 
Psoromic acid (PA) is a natural product from lichens and has recently been identified as a 
specific inhibitor of RabGGTase216. It shows good selectivity for RabGGTase compared to 
FTase and GGTase-I. The IC50 towards RabGGTase is 1.6 µM and, 114 and 78 µM towards 
FTase and GGTase-I, respectively. The Kd value of this compound for RabGGTase was 
determined to be 130 nM216. The chemical structure of psoromic acid is shown in Figure 4.34. 
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Figure 4.34: Chemical structures of Psoromic acid (PA). 
After substantial experimentation, crystals of the complex of PA with a truncated version of 
RabGGTase were obtained and the structure was determined with a resolution of 2.5 Å. 
The preparation of the truncated RabGGTase:PA complex crystals, the collection of 
diffraction data, the subsequent processing and the final structural determination were 
performed as described in the structural study of the truncated RabGGTase in complex with 
inhibitor KT90102. The crystals did not change their space group after soaking. Full data 
collection and refinement statistics are summarized in Table 4.2. Structure factors and 
coordinates will be deposited in the Protein Data Bank with entry codes zzzz 
(RabGGTase_αΔLRRΔIG: PA). 
 
Figure 4.35: Difference electron density of PA, displayed at 2 σ. The electron density was calculated prior 
to the incorporation of the ligand into the model. 
Initial difference electron density maps (fofc-map) showed strong positive density at the 
entrance of the central hydrophobic cavity of the enzyme (Figure 4.35). One psoromic acid 
molecule was fitted into the density observed and final rounds of refinement were performed 
using a restraints library generated with PRODRG. However, the exact binding mode of this 
compound in the structure could not be strictly determined. There were in all five possibilities 
for the binding.of PA. This was caused by two reasons. One reason is the low aqueous 
solubility of PA, leading to low occupancy of the inhibitor in crystals. The other reason is the 
similar substituted groups at both phenyl rings of PA, which made special difficulty to 
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determine the binding mode because the electron densities of both substituted phenyl groups 
appeared similar. Though some docking studies were performed by S. Wetzel, but with 
limited success since the cavity was very large. Then the derivates of PA (including active 
and inactive compounds), synthesized by Dr. C. Deraeve, were modeled into structure by 
using the five possible binding modes. Analysis the modeled structures and the inhibitory 
activities of these derivates suggests that only the binding mode shown in Figure 4.36 is 
possible. According to the modeled structures, most of inactive derivates of PA would clash 
with the enzyme by using this binding mode, but would fit well by using the other four 
binding modes. Finally, the binding mode of PA to RabGGTase was proposed (Figure 4.35 
and Figure 4.36) by the structural determination in context with structure-activity relationship 
(SAR). 
The quality of the final electron density map together with a comparison of the refined 
temperature factors of PA (~100 Å2) and the surrounding protein residues (~50 Å2) suggest 
that the occupancy of PA is approximately 50%. 
The final model of the RabGGTase_αΔLRRΔIG:PA complex contains 6 water molecules, one 
PA molecule and one Zn2+ ion. The structure was refined to an R-factor of 22.7 % and Rfree of 
29.8 %. The model of the complex contains one α/β heterodimer in the asymmetric unit. 90.6 
% of the total residues for the complex structure lie in the most favoured region of the 
Ramachandran plot (PROCHECK). Most of the residues with poorer electron density are 
located in the additionally allowed regions, with no residue in the disallowed region. 
The structure complex demonstrates that PA binds at the entrance of the central hydrophobic 
funnel (Figure 4.36). The binding of this inhibitor does not induce a significant change in the 
structure of the active site. Superimposition of this RabGGTase:PA structure, the 
RabGGTase:GGPP structure and the related GGTase-I in complex with a peptide substrate 
and a nonreactive GGPP analogue (PDB code 1TNB)103 reveals that the inhibitor occupies the 
binding site of Rab C-terminus (Figure 4.36 A), but has a weak influence on the lipid binding 
site. 
Besides the hydrophobic interaction between RabGGTase and PA, the lactone on the seven-
membered ring of PA coordinates the Zn2+ ion via a water molecule. Additionally, the 
phenolic hydroxy group of PA forms a strong hydrogen bond (2.6 Å) with the side chain of 
Tyr44 of the β subunit and a weak hydrogen bond (3.3 Å) with Asp61 of the α subunit (Figure 
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4.36 B). It seems that both coordinations serve as ‘anchors’ for the binding of PA at the 
entrance of the cavity. Superimposition of this structure, the GGTase-I structure (PDB code 
1N4P)89 and the FTase structure (PDB code 1FT1)91 illustrates the molecular basis for its high 
specificity for RabGGTase compared to GGTase-I and FTase (Figure 4.36 C). As described 
above one ‘anchor’ is formed by residues Tyr44β and Asp61α in RabGGTase, whereas the 
corresponding positions in GGTase-I are occupied by Thr45β and Ala129α, in FTase by 
Ala98β and Ala129α. The lack of this ‘anchor’ in GGTase-I and FTase is probably 
responsible for the much higher IC50-values towards both enzymes. 
Analysis of the complex structure reveals several attachment points in the immediate vicinity 
of the bound inhibitor that could serve to improve the affinity and specificity of the inhibitors. 
One site formed by Arg232β and Lys235β is a positively charged cluster, which coordinates 
the phosphate moiety of GGPP. The other sites are composed of residue His190β positioned 
to the methyl ether moiety of PA and of residue Arg144β positioned to the carboxylic acid 
group of PA. 
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Figure 4.36: Structural analysis of truncated RabGGTase in complex with psoromic acid. (A) 
Superimposition of the of RabGGTase:PA structures, the RabGGTase:GGPP structure and the GGTase-I 
in complex with substrate peptide KCVIF and a non-hydrolysable analogue of GGPP (PDB code 1TNB). 
The active site of RabGGTase in complex with inhibitors is shown in surface representation. The GGPP 
bound to RabGGTase and the substrate peptide KCVIF in the GGTase-I complex are shown in line 
representation and coloured in green and cyan, respectively. The Zn2+ ion is represented in yellow sphere, 
while the inhibitors are displayed in stick and in atomic colours. (B) Interactions of compound PA with 
the active site of RabGGTase. The α and β subunit of RabGGTase are displayed as green and gray 
cartoons, respectively. The inhibitors and interacting side chains of RabGGTase are displayed as sticks 
coloured by atom type. Blue dashes indicate hydrogen bonds, the Zn2+ ion and water molecule 
participating in the interaction are shown as yellow and red spheres, respectively. (C) Superimposition of 
this complex structure and the structure of GGTase-I (PDB code 1N4P) and FTase (PDB code 1FT1) 
reveals the molecular basis for its high specificity for RabGGTase compared to GGTase-I and FTase. 
RabGGTase, GGTase-I and FTase are displayed as gray, cyan and blue cartoon, respectively, while the 
Zn2+ ion is shown as yellow sphere. The residues Y44β and D61α in RabGGTase and the corresponding 
residues in GGTase-I Thr45β and Ala129α, in FTase Ala98β and Ala129α, are displayed as stick. 
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Table 4.2 Data collection statistics for the truncated FTase, RabGGTase and its complexes. 
Data collection RabGGTase FTase RabGGTase:GGPP 
Wavelength (Å)/Beamline 0.9800/ SLS-PXII 0.9825 / SLS-PXII 1.0007/ SLS-PXII 
Resolution (Highest Shell, Å) 29.4 – 1.8 (1.9 – 1.8) 30.0 – 2.8 (2.85 – 2.8) 29.4 – 1.85 (1.9 – 1.85) 
Space group P212121 P61 P212121 
Cell constants (Å; °) a=66.7, b=90.6, 
c=114.1; α=β=γ=90 
a=172.9, b=172.9, 
c=70.5; α=β=90, γ=120 
a=67.3,b=90.6, 
c=114.5; α=β=γ=90 
VM 2.5 2.5 2.5 
Total measurements 294558 181484 278888 
Unique reflections 64333 29762 60104   
Average redundancy 4.6 (3.4) 6.1 (6.3) 4.6 (4.5) 
I/σ 16.4 (4.7) 12.3 (3.9) 20.5 (3.9) 
Completeness (%) 99.3 (99.7) 99.6 (99.9) 99.5 (99.5) 
Rsyma 6.3 (27.5) 33.9 (68.0) 4.2 (44.6) 
Wilson B-factor (Å2) 30 54.55 48.4 
Refinement    
Resolution (Highest Shell, Å) 1.8 (1.85 – 1.8) 2.8 (2.87 – 2.8) 1.85 (1.9 – 1.85) 
Rb 18.52 17.69 21.32 
Rfreec 21.77 23.22 24.99 
rmsd bonds (Å)/angles (°) 0.008/1.267 0.019/1.786 0.011/1.392 
B-factor deviation 
bonds/angles (Å2) 
main chain 
side chain 
 
 
0.943/1.657 
2.111/3.069 
 
 
1.595/2.725 
3.123/4.977 
 
 
1.183/2.002 
2.367/3.327 
Residues in Ramachandran Core (%)d 90.8 86.5 91.0 
Protein atoms 
Solvent atoms 
Ligand atoms 
5016 
394 
3 
5749 
54 
1 
4869 
127 
32 
Average B-factor (Å2) 24.18 53.01 45.71 
PDB accession code    
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Table 4.2: Data collection statistics for the truncated FTase, RabGGTase and its complexes (continuous). 
Data collection RabGGTase:FPP RabGGTase:GGMP RabGGTase:GGTP 
Wavelength (Å)/Beamline 0.9998/ SLS-PXII 0.9794/ SLS-PXII 1.0002 / SLS-PXII 
Resolution (Highest Shell, Å) 29.4 – 1.85 (1.9 – 1.85) 29.7 – 2.55 (2.6 – 2.55) 29.4 – 2.0 (2.1 – 2.0) 
Space group P212121 P212121 P212121 
Cell constants (Å; °) a=66.9, b=90.9, 
c=114.2; α=β=γ=90 
a=67.5, b=92.2, 
c=114.5; α=β=γ=90 
a=66.2, b=91.2, 
c=115.4; α=β=γ=90 
VM 2.5 2.5 2.5 
Total measurements 339708 94709 236439 
Unique reflections 59021 23795 47955 
Average redundancy 5.8 (5.8) 4.0 (4.1) 4.9 (5.0) 
I/σ 21.0 (3.4) 13.3 (3.1) 21.2 (4.9) 
Completeness (%) 98.2 (98.0) 99.3 (99.9) 99.8 (99.9) 
Rsyma 4.9 (56.5) 6.5 (40.0) 5.3 (32.7) 
Wilson B-factor (Å2) 34.7 56.4 31.79 
Refinement    
Resolution (Highest Shell, Å) 1.85 (1.9 – 1.85) 2.55 (2.62 – 2.55) 2.0 (2.05 – 2.0) 
Rb 20.41 21.67 19.58 
Rfreec 23.53 29.06 23.49 
rmsd bonds (Å)/angles (°) 0.010/1.349 0.015/1.635 0.008/1.240 
B-factor deviation 
bonds/angles (Å2) 
main chain 
side chain 
 
 
0.982/1.775 
1.871/2.880 
 
 
1.356/2.393 
2.429/3.754 
 
 
0.816/1.448 
1.506/2.228 
Residues in Ramachandran Core (%)d 91.2 88.5 91.3 
Protein atoms 
Solvent atoms 
Ligand atoms 
5137 
215 
26 
4922 
36 
26 
4897 
290 
35 
Average B-factor (Å2) 31.33 52.69 27.62 
PDB accession code    
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Table 4.2: Data collection statistics for the truncated FTase, RabGGTase and its complexes (continuous). 
Data collection RabGGTase 
Ser-Cys-Ser-Cys(GG) 
RabGGTase 
Ser-Cys(GG)-Ser-Cys 
RabGGTase 
Ser-Cys(GG)-Ser-Cys(GG) 
Wavelength (Å)/Beamline 0.9999/ SLS-PXII 0.9825/ SLS-PXII 0.9841 / SLS-PXII 
Resolution (Highest Shell, Å) 29.4 – 1.9 (1.95 – 1.9) 29.4 – 2.1 (2.15 – 2.1) 29.4 – 2.0 (2.05 – 2.0) 
Space group P212121 P212121 P212121 
Cell constants (Å; °) a=67.0, b=90.6, 
c=114.4; α=β=γ=90 
a=67.1, b=90.9, 
c=114.3; α=β=γ=90 
a=67.4, b=91.2, 
c=114.6; α=β=γ=90 
VM 2.5 2.5 2.5 
Total measurements 996311 165055 350190 
Unique reflections 55522 41204   48343 
Average redundancy 17.9 (16.3) 4.0 (4.1) 7.2 (7.4) 
I/σ 24.6 (4.6) 14.4 (4.2) 20.7 (4.3) 
Completeness (%) 99.8 (99.4) 99.2 (100) 99.8 (99.9) 
Rsyma 10.3 (91.0) 7.5 (47.6) 6.5 (66.6) 
Wilson B-factor (Å2) 29.1 38.8 37.9 
Refinement    
Resolution (Highest Shell, Å) 1.9 (1.95 – 1.9) 2.1 (2.1 – 2.15) 2.0 (2.05 – 2.0) 
Rb 16.05 17.22 18.12 
Rfreec 22.07 23.27 24.05 
rmsd bonds (Å)/angles (°) 0.021/1.833 0.020/1.787 0.019/1.730 
B-factor deviation 
bonds/angles (Å2) 
main chain 
side chain 
 
 
1.899/2.833 
4.441/6.039 
 
 
1.703/2.680 
4.076/5.666 
 
 
1.812/2.741 
4.140/5.617 
Residues in Ramachandran Core (%)d 91.9 92.7 92.3 
Protein atoms 
Solvent atoms 
Ligand atoms 
4926 
386 
17 
4962 
153 
14 
4959 
203 
22 
Average B-factor (Å2) 25.21 36.17 33.57 
PDB accession code    
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Table 4.2: Data collection statistics for the truncated FTase, RabGGTase and its complexes (continuous). 
Data collection RabGGTase:MT650 RabGGTase:MT670 RabGGTase:KT90102 
Wavelength (Å)/Beamline 0.9797 / SLS-PXII 0.9816 / SLS-PXII 0.9794 / SLS-PXII 
Resolution (Highest Shell, Å) 20.0 – 2.3 (2.4 – 2.3) 29.4 – 2.2 (2.25 – 2.2) 29.4 – 1.95 (2.0 – 1.95) 
Space group P212121 P212121 P212121 
Cell constants (Å; °) a=66.2, b=91.7, 
c=115.4; α=β=γ=90 
a=66.5, b=90.6, 
c=115.2; α=β=γ=90 
a=66.4, b=90.6, 
c=114.9; α=β=γ=90 
VM 2.5 2.5 2.5 
Total measurements 181449 168703 415495 
Unique reflections 31830 35201 50656 
Average redundancy 5.7 (5.8) 4.8 (4.7) 8.2 (8.2) 
I/σ 20.0 (4.7) 17.1 (3.8) 20.4 (4.1) 
Completeness (%) 99.7 (100.0) 97.6 (99.0) 98.9 (100.0) 
Rsyma 5.2 (40.7) 5.5 (41.7) 9.0 (102.6) 
Wilson B-factor (Å2) 50.3 43.1 37.44 
Refinement    
Resolution (Highest Shell, Å) 2.3 (2.36 – 2.3) 2.2 (2.26 – 2.2) 1.95 (2.0 – 1.95) 
Rb 18.92 21.03 20.00 
Rfreec 25.63 28.33 24.00 
rmsd bonds (Å)/angles (°) 0.019/1.622 0.018/1.761 0.010/1.258 
B-factor deviation 
bonds/angles (Å2) 
main chain 
side chain 
 
 
0.878/1.451 
2.100/2.958 
 
 
1.392/2.274 
3.191/4.536 
 
 
1.114/1.885 
3.054/4.967 
Residues in Ramachandran Core (%)d 90.6 89.4 91.3 
Protein atoms 
Solvent atoms 
Ligand atoms 
5017 
191 
47 
4891 
95 
47 
4881 
183 
57 
Average B-factor (Å2) 31.26 44.34 33.73 
PDB accession code 3C72   
 
 
 
 
Results and discussions
 
 
 
98
Table 4.2: Data collection statistics for the truncated FTase, RabGGTase and its complexes (continuous). 
Data collection RabGGTase:PA 
Wavelength (Å)/Beamline 1.0007 / SLS-PXII 
Resolution (Highest Shell, Å) 20.2 – 2.5 (2.6 – 2.5) 
Space group P212121 
Cell constants (Å; °) a=65.6, b=92.0, 
c=116.0; α=β=γ=90 
VM 2.5 
Total measurements 109349 
Unique reflections 24579 
Average redundancy 4.4 (4.5) 
I/σ 21.4 (3.7) 
Completeness (%) 98.5 (99.3) 
Rsyma 4.0 (46.9) 
Wilson B-factor (Å2) 67.3 
Refinement  
Resolution (Highest Shell, Å) 2.5 (2.56 – 2.5) 
Rb 22.69 
Rfreec 29.82 
rmsd bonds (Å)/angles (°) 0.016/1.602 
B-factor deviation 
bonds/angles (Å2) 
main chain 
side chain 
 
 
1.446/2.409 
2.883/4.192 
Residues in Ramachandran Core (%)d 90.6 
Protein atoms 
Solvent atoms 
Ligand atoms 
4689 
6 
27 
Average B-factor (Å2) 64.40 
PDB accession code  
aRsym = ΣΣ I(h)j - <I(h)> / ΣΣ I(h)j where I(h)j is the measured diffraction intensity and the summation includes 
all observations. 
bR is the R-factor = ( Σ | FO | - Σ | FC | ) / Σ | FO |. 
cRfree is the R-factor calculated using 5 % of the data that were excluded from the refinement. 
dRamachandran core refers to the most favoured regions in the φ/ψ-Ramachandran plot as defined by Laskowski 
et al.(Laskowski et al., 1993). 
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5 Summary and Conclusion 
5.1 Summary and Conclusion (English) 
The structural analysis of RabGGTase was previously hampered by difficulties in obtaining 
well diffracting crystals in a reliable and reproducible manner. In this project, an engineered 
rat RabGGTase without the LRR and IG domains was designed and produced in recombinant 
from E. coli. This RabGGTase mutant was able to prenylate Rab7 with an efficiency 
comparable to that of wild type enzyme. This confirms an earlier proposal that the LRR and 
IG domains of mammalian RabGGTase are not involved in the prenylation reaction and play 
another, as yet unidentified function. Unlike wild type enzyme the RabGGTase_αΔLRRΔIG 
mutant could be easily crystallized and yielded high-quality crystals which produced 
diffraction data allowing structure determination to a resolution of 1.8 Å. As expected, the 
overall structure of the engineered enzyme changed very little compared to the wild type 
enzyme and was similar to that of FTase and GGTase-I.  
The availability of an easily crystallisable variant of RabGGTase enabled solution of it s 
structure in complex with the isoprenoid substrate, GGPP, to 1.85 Å resolution. This structure 
has completed the picture of enzyme:substrate complexes for the protein prenyltransferase 
family and provided mechanistic insights into the lipid substrate specificity of protein 
prenyltransferases. Analysis of the structure of the complex revealed several critical amino 
acids at the bottom of hydrophobic lipid binding site that play a essential role in selecting the 
respective isoprenoid substrate. Compared to FTase and GGTase-I, RabGGTase has an 
expanded lipid binding pocket which enables it to accept  bulky substrates such as 
biotingeranyl pyrophosphate (Biotin-GPP) 202. By comparing all three prenytransferases in 
complex with lipid substrates we were able to design the mutants of FTase and GGTase-I 
capable of conjugating Biotin-GPP to their cognate protein substrates. These mutants can be 
used to rapidly identity, isolate and characterize prenylatable proteins in mammalian cell. This 
provides a new technological venue in protein prenyltransferase research. 
The structural and biochemical data obtained in this work suggested that FPP can serve as a 
lipid substrate of RabGGTase. Interestingly, we showed that GGMP and GGTP can not serve 
as lipid donors in Rab prenylation. The structures of the truncated RabGGTase complexed 
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with FPP, GGMP and GGTP have been determined at 1.85 Å, 2.55 Å and 2.0 Å resolution, 
respectively. These structures provide insight into the mode of isoprenoid binding to 
RabGGTase. The RabGGTase:GGMP complex is very similar to the complex with GGPP, 
while the complex with GGTP shows significant differences. Remarkably, comparison of the 
structures of GGPP and FPP bound to the RabGGTase mutant reveals the molecular basis of 
the large difference in their binding affinities. FPP has significantly fewer hydrogen bonds 
between the diphosphate group and the active site, and this in combination with the reduction 
of hydrophobic interactions by the lack of one isoprene unit in FPP leads to >100 times 
reduction in the affinity of FPP relative to GGPP for RabGGTase.  
To complete the structural picture of the RabGGTase cycle, we attempted co-crystallization of 
RabGGTase with prenylated peptides mimicking reaction intermediates and the final products 
of Rab7 prenylation. The structures of the truncated RabGGTase in complex with Ser-Cys-
Ser-Cys(GG), Ser-Cys(GG)-Ser-Cys and Ser-Cys(GG)-Ser-Cys(GG) mimiking mono- and di-
prenylated Rab7, were determined at 1.9 Å, 2.1 Å and 2.0 Å resolution, respectively. These 
prenylated peptides bind to RabGGTase with comparable affinities (Kd ca. 1-2 µM). The lack 
of electron density for the peptide chain in these structures is caused by the fact that 
RabGGTase cannot and indeed does not need to anchor the C-terminus of the Rab substrates. 
The invisibility of the second lipid chain in the case of di-prenylated peptide indicates that, 
unlike the CAAX-prenyltransferases, an ‘exit groove’ is not available for stabilizing of the 
dislodged prenyl group. Based on these structures and on available biochemical data on Rab 
prenylation, a reaction cycle is proposed for RabGGTase. 
The structures of the truncated RabGGTase in complex with inhibitors MT650, MT670, 
KT90102 and psoromic acid have been determined at 2.3 Å, 2.2 Å, 1.95 Å and 2.5 Å 
resolution, respectively. Analysis of these complex structures reveals the molecular basis for 
their inhibitory activities, which relies predominantely on blocking the putative peptide 
binding site of RabGGTase. These observations are consistent with the available kinetic 
results. From the analysis of RabGGTase:inhibitor structures it transpires that several 
modifications of the chemical structures of these inhibitors could be preformed to improve the 
affinity and specificity of the inhibitors by structure-guided ligand design. Inhibitors with 
increased potency and specificity for RabGGTase are candidates for anti-cancer therapy and 
anti-osteoporosis therapy. 
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5.2 Summary and Conclusion (Deutsch) 
Schwierigkeiten in der verlässlichen und reproduzierbaren Herstellung gut streuender 
Kristalle erschwerte bislang die strukturelle Analyse von RabGGTase. 
In diesem Projekt wurde daher eine veränderte RabGGTase aus Ratte ohne die LRR– und IG- 
Domäne generiert und rekombinant in E. coli hergestellt. Diese RabGGTase-Mutante war in 
der Lage, Rab7 mit einer dem Wildtyp vergleichbaren Effizienz zu prenylieren. Dieser 
Umstand bestätigt eine frühere Vermutung, dass die LRR- und IG-Domänen von Säuger-
RabGGTase nicht an der Prenylierungs-Reaktion beteiligt sind und eine andere, bislang 
unbekannte Funktion haben.  
 Im Gegensatz zum Wildtyp-Enzym konnte aus der αΔLRRΔIG-Mutante von RabGGTase 
einfach hochwertige Kristalle erhalten werden. Die erhaltenen Diffraktionsdaten erlaubte eine 
Strukturaufklärung mit einer Auflösung von 1,8 Å. Wie erwartet, zeigte die Gesamtstruktur 
des modifizierten Enzyms nur sehr geringe Unterschiede zum Wildtypenzym und war den 
Strukturen von FTase und GGTase-I ähnlich.  
Die Verfügbarkeit einer einfach kristallisierbaren Variante von RabGGTase ermöglichte die 
Strukturlösung des Enzyms im Komplex mit dem Isoprenoid-Substrats GGPP mit einer 
Auflösung von 1,85 Å. Die Struktur vervollständigte das Bild der Enzym-Substrat-Komplexe 
der Prenyltransferase-Familie und ermöglichte Einblicke in den Mechanismus der Lipid-
Substratspezifität der Prenyltransferasen. Die Analyse der Komplex-Struktur zeigte am Boden 
der hydrophoben Lipid-Bindungsstelle mehrere essentielle Aminosäuren, die eine 
entscheidende Rolle in der Selektion der betreffenden Isoprenoid-Substrate haben. Im 
Gegensatz zu FTase und GGTase-I besitzt die RabGGTase eine ausgedehnte Lipid-
Bindetasche, die es erlaubt große Substrate, wie Biotingeranyl-Pyrophosphat (Biotin-GPP)202 
zu binden. Ein Vergleich aller drei Prenyltransferasen im Komplex mit den Lipid-Substraten 
ermöglichte das Design von FTase- und GGTase-I-Mutanten, die in der Lage waren Biotin-
GPP an ihre entsprechenden Protein-Substrate zu konjugieren. 
Die in dieser Arbeit erhaltenen strukturellen und biochemischen Daten lassen vermuten, daß 
FPP als Lipid-Substrat für RabGGTase fungieren kann. Interessanterweise konnten wir 
zeigen, daß GGMP bzw. GGTP nicht als Lipid-Donoren der Rab-Prenylation fungieren 
können. Die Strukturen der verkürzten RabGGTase im Komplex mit FPP, GGMP oder GGTP 
wurden mit 1,85 Å, 2,55 Å bzw. 2,0 Å Auflösung bestimmt. Diese Stukturen ermöglichten 
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Einblicke in den Bindungsmodus des Isoprenoids an die RabGGTase. Der 
RabGGTase:GGMP-Komplex ist sehr ähnlich zum GGPP-Komplex, wohingegen der GGTP-
Komplex signifikante Unterschiede zeigt. Der Vergleich der Strukturen von RabGGTase 
gebundenem GGPP und FPP läßt die molekulare Grundlage für die großen Unterschiede in 
den Bindungsaffinitäten erkennen. FPP weist signifikant weniger Wasserstoffbrücken 
zwischen der Diphosphat-Gruppe und dem aktiven Zentrum auf. Dies und die geringere 
Anzahl an hydrophoben Interaktionen durch das Fehlen einer Isopren-Einheit in FPP führt zu 
einer mehr als 100-fach erniedrigten Affinität von FPP zu RabGGTase im Vergleich zu 
GGPP. 
Um das strukturelle Bild des RabGGTase- Zyklus zu vervollständigen, wurden 
Cokristallisationn von RabGGTase mit prenylierten Peptiden durchgeführt, welche als 
Analoga für Reaktionsintermediate bzw. Endprodukte der Rab7-Prenylierung dienten. Die 
Strukturen der verkürzten RabGGTase im Komplex mit Ser-Cys-Ser-Cys(GG), Ser-Cys(GG)-
Ser-Cys bzw. Ser-Cys(GG)-Ser-Cys(GG) als Analoga für mono- und diprenyliertes Rab7 
wurden mit 1,9 Å, 2,1 Å bzw. 2,0 Å Auflösung bestimmt. Diese prenylierten Peptide binden 
mit vergleichbaren Affinitäten (Kd ca. 1-2 µM) an RabGGTase. Das Fehlen einer 
Elektronendichte für die Peptidkette in den Strukturen ist darin begründet, daß RabGGTase 
nicht in der Lage ist und nicht in der Lage sein muss, den C-Terminus des Rab-Substrates zu 
verankern. Die Nichtsichtbarkeit der zweiten Lipid-Kette im Falle des diprenylierten Peptids 
zeigt, dass, im Gegensatz zu den CAAX-Prenyltransferasen, keine „Ausgangsfurche“ zur 
Stabilisierung der entfernteren Prenylgruppe vorhanden ist. Auf Grundlage der erhaltenen 
Strukturen und verfügbaren biochemischen Daten zur Rab-Prenylierung konnte ein 
Reaktionszyklus für RabGGTase aufgestellt werden. 
Die Strukturen von verkürzter RabGGTase im Komplex mit den Inhibitoren MT650, MT670, 
KT90102 und psoromic acid wurden mit einer Auflösung von 2,3 Å, 2,2 Å, 1,95 Å bzw. 2,5 
Å bestimmt. Die Analyse dieser Komplex-Strukturen zeigte die molekulare Grundlage ihrer 
inhibitorischen Aktivitäten, die in erster Linie in der Blockierung der vermuteten Peptid-
Bindungsstelle von RabGGTase besteht. Diese Beobachtungen stehen in Übereinstimmung 
mit verfügbaren kinetischen Ergebnissen. Auf Grundlage der RabGGTase:Inhibitor-
Strukturen konnten verschiedene chemische Modifikationen an den  Inhibitorstrukturen 
ausgeführt werden, um die Affinität und Spezifität der Inhibitoren durch Stuktur-gesteuertes 
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Ligand-Design zu verbessern. Inhibitoren mit gesteigerter Wirksamkeit und Spezifität für 
RabGGTasen sind Kandidaten für Anti-Krebs- und Anti-Osteoporose-Therapien. 
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